0001193125-15-162309.txt : 20150430 0001193125-15-162309.hdr.sgml : 20150430 20150430164640 ACCESSION NUMBER: 0001193125-15-162309 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150430 DATE AS OF CHANGE: 20150430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 15819576 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 10-K/A 1 d917300d10ka.htm 10-K/A 10-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-K/A

Amendment No. 1

 

 

 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended December 31, 2014

or

 

¨ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from              to             

Commission File Number: 0-24006

 

 

NEKTAR THERAPEUTICS

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   94-3134940

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of principal executive offices and zip code)

415-482-5300

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

  

Name of Each Exchange on Which Registered

Common Stock, $0.0001 par value   NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:

None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  x    No  ¨

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days)    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2)    Yes  ¨    No  x

The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant’s common stock on the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2014, as reported on the NASDAQ Global Select Market, was approximately $1,625,943,780. This calculation excludes approximately 457,759 shares held by directors and executive officers of the registrant. Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant.

As of April 23, 2015, the number of outstanding shares of the registrant’s common stock was 131,526,201.

 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of registrant’s definitive Proxy Statement to be filed for its 2015 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.

EXPLANATORY NOTE

Nektar Therapeutics (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K (this “Amendment”) for the year ended December 31, 2014, which was originally filed on February 26, 2015 (“Original Filing”), to amend and restate in its entirety the Item 5 of Part II of the Original Filing. The Original Filing inadvertently included a graph depicting the five-year comparison of cumulative return for the period of 2008 to 2013 rather than 2009 to 2014. The only change in this Amendment is to replace that comparison graph with the updated comparison graph from 2009 to 2014.

Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”), this Amendment amends and restates in its entirety Item 5 of Part II of the Original Filing and contains new certifications pursuant to Rule 13a-14 promulgated under the Exchange Act. This Amendment contains only the sections and exhibits to the Original Filing that are being amended and restated, and those unaffected parts or exhibits are not included herein. This Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosure contained therein to reflect events that have occurred since the filing of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings, if any, made with the United States Securities and Exchange Commission subsequent to the filing of the Original Filing, including the amendments to those filings, if any.

 

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock trades on The NASDAQ Global Select Market under the symbol “NKTR.” The table below sets forth the high and low closing sales prices for our common stock as reported on The NASDAQ Global Select Market during the periods indicated.

 

     High      Low  

Year Ended December 31, 2013:

      

1st Quarter

    $ 11.06       $ 7.54   

2nd Quarter

      11.70         8.83   

3rd Quarter

      13.96         10.45   

4th Quarter

      12.56         8.96   

Year Ended December 31, 2014:

      

1st Quarter

    $ 14.96       $ 11.68   

2nd Quarter

      14.31         10.53   

3rd Quarter

      14.48         10.55   

4th Quarter

      17.05         12.07   

Holders of Record

As of February 20, 2015, there were approximately 212 holders of record of our common stock.

Dividend Policy

We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future.

There were no sales of unregistered securities and there were no common stock repurchases made during the year ended December 31, 2014.

Securities Authorized for Issuance Under Equity Compensation Plans

Information regarding our equity compensation plans as of December 31, 2014 is disclosed in Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of this Annual Report on Form 10-K and is incorporated herein by reference from our proxy statement for our 2015 annual meeting of stockholders to be filed with the SEC pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

1

Performance Measurement Comparison

The material in this section is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.

The following graph compares, for the five-year period ended December 31, 2014, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i) the NASDAQ Composite Index, (ii) the NASDAQ Pharmaceutical Index, (iii) the RGD SmallCap Pharmaceutical Index, (iv) the NASDAQ Biotechnology Index and (v) the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December 31, 2010, December 31, 2011, December 31, 2012, December 31, 2013 and December 31, 2014. The graph assumes that $100 was invested on December 31, 2009 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RGD SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price performance.

 

 

LOGO

 

2

Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Amendment No. 1 to the Annual Report on Form 10-K.

 

Exhibit

Number

  

Description of Documents

  2.1(1)   Asset Purchase Agreement, dated October 20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+
  3.1(2)   Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.
  3.2(3)   Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.
  3.3(4)   Certificate of Ownership and Merger of Nektar Therapeutics.
  3.4(5)   Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.
  3.5(6)   Amended and Restated Bylaws of Nektar Therapeutics.
  4.1   Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, and 3.5.
  4.2(4)   Specimen Common Stock certificate.
  4.3(8)   Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due 2017.
10.1(9)   Employee Stock Purchase Plan, as amended and restated.++
10.2(10)   2000 Non-Officer Equity Incentive Plan, as amended and restated.++
10.3(10)   2000 Equity Incentive Plan, as amended and restated.++
10.4(10)   2008 Equity Incentive Plan, as amended and restated.++
10.5(11)   2012 Performance Incentive Plan.++
10.6(18)   Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++
10.7(18)   Amended and Restated Compensation Plan for Non-Employee Directors.++
10.8(12)   401(k) Retirement Plan.++
10.9(10)   Discretionary Incentive Compensation Policy.++
10.10(10)   Amended and Restated Change of Control Severance Benefit Plan.++
10.11(13)   Form of Severance Letter for executive officers of the company.++
10.12(1)   Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Howard W. Robin.++
10.13(1)   Amended and Restated Letter Agreement, executed effective on December 1, 2008, with John Nicholson.++
10.14(14)   Letter Agreement, executed effective on December 10, 2009, with Stephen K. Doberstein, Ph.D.++
10.15(19)   Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko Ghosh.++

 

3

10.16(20)   Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++
10.17(13)   Amended and Restated Built-to-Suite Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August 17, 2004, as amended on January 11, 2005 and July 19, 2007.
10.18(16)   Sublease, dated as of September 30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+
10.19(15)   Settlement Agreement and General Release, dated June 30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.
10.20(14)   Co-Development, License and Co-Promotion Agreement, dated August 1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as amended.+
10.21(1)   Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September 26, 2005, as amended.+
10.22(1)   Exclusive License Agreement, dated December 31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+
10.23(14)   Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October 29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing, Limited.+
10.24(16)   License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September 20, 2009.+
10.25(7)   12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.
10.26(18)   Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February 28, 2013, by and between Nektar Therapeutics and Wells Fargo Bank, National Association.
10.27(8)   Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank, National Association, as escrow agent.
10.28(17)   Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+
10.29(18)   Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+
10.30(19)   Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.
21.1(20)   Subsidiaries of Nektar Therapeutics.
23.1(20)   Consent of Independent Registered Public Accounting Firm.
24   Power of Attorney (reference is made to the signature page).
31.1(21)   Certification of Nektar Therapeutics’ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).
31.2(21)   Certification of Nektar Therapeutics’ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).
32.1*   Section 1350 Certifications.
101**   The following materials from Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements.

 

4

 

+ Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
++ Management contract or compensatory plan or arrangement.
* Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.
** XBRL information is filed with Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2014.
(1) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2008.
(2) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1998.
(3) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2000.
(4) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 23, 2003.
(5) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2009.
(6) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on April 11, 2011.
(7) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 10, 2012.
(8) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 11, 2012.
(9) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-98321), filed on August 19, 2002.
(10) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2011.
(11) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 3, 2012.
(12) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.
(13) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
(14) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2010.
(15) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.
(16) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.
(17) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
(18) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
(19) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2013.
(20) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2014.
(21) Filed herewith.

 

5

SIGNATURES

Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City and County of San Francisco, State of California on April 30, 2015.

 

By:  

/s/    JOHN NICHOLSON

 

John Nicholson

Senior Vice President and Chief Financial Officer

 

By:  

/S/    JILLIAN B. THOMSEN

 

Jillian B. Thomsen

Senior Vice President, Finance and Chief Accounting Officer

 

6

KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Nicholson and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:

 

Signature

   

Title

  

Date

/S/    HOWARD W. ROBIN

Howard W. Robin

    Chief Executive Officer, President and Director (Principal Executive Officer)   April 30, 2015

/S/    JOHN NICHOLSON

John Nicholson

    Senior Vice President and Chief Financial Officer (Principal Financial Officer)   April 30, 2015

/S/    JILLIAN B. THOMSEN

Jillian B. Thomsen

    Senior Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)   April 30, 2015

/S/    *

Robert B. Chess

    Director, Chairman of the Board of Directors   April 30, 2015

/S/    *

R. Scott Greer

    Director   April 30, 2015

/S/    *

Joseph J. Krivulka

    Director   April 30, 2015

/S/    *

Christopher A. Kuebler

    Director   April 30, 2015

/S/    *

Lutz Lingnau

    Director   April 30, 2015

/S/    *

Susan Wang

    Director   April 30, 2015

/S/    *

Roy A. Whitfield

    Director   April 30, 2015

/S/    *

Dennis L. Winger

    Director   April 30, 2015

 

*By:  

/s/    JILLIAN B. THOMSEN

  Jillian B. Thomsen
  Senior Vice President, Finance and Chief Accounting Officer

 

7

Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Amendment No. 1 to the Annual Report on Form 10-K.

 

Exhibit

Number

  

Description of Documents

  2.1(1)   Asset Purchase Agreement, dated October 20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+
  3.1(2)   Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.
  3.2(3)   Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.
  3.3(4)   Certificate of Ownership and Merger of Nektar Therapeutics.
  3.4(5)   Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.
  3.5(6)   Amended and Restated Bylaws of Nektar Therapeutics.
  4.1   Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, and 3.5.
  4.2(4)   Specimen Common Stock certificate.
  4.3(8)   Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due 2017.
10.1(9)   Employee Stock Purchase Plan, as amended and restated.++
10.2(10)   2000 Non-Officer Equity Incentive Plan, as amended and restated.++
10.3(10)   2000 Equity Incentive Plan, as amended and restated.++
10.4(10)   2008 Equity Incentive Plan, as amended and restated.++
10.5(11)   2012 Performance Incentive Plan.++
10.6(18)   Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++
10.7(18)   Amended and Restated Compensation Plan for Non-Employee Directors.++
10.8(12)   401(k) Retirement Plan.++
10.9(10)   Discretionary Incentive Compensation Policy.++
10.10(10)   Amended and Restated Change of Control Severance Benefit Plan.++
10.11(13)   Form of Severance Letter for executive officers of the company.++
10.12(1)   Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Howard W. Robin.++
10.13(1)   Amended and Restated Letter Agreement, executed effective on December 1, 2008, with John Nicholson.++
10.14(14)   Letter Agreement, executed effective on December 10, 2009, with Stephen K. Doberstein, Ph.D.++
10.15(19)   Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko Ghosh.++
10.16(20)   Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++
10.17(13)   Amended and Restated Built-to-Suite Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August 17, 2004, as amended on January 11, 2005 and July 19, 2007.

 

8

10.18(16)   Sublease, dated as of September 30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+
10.19(15)   Settlement Agreement and General Release, dated June 30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.
10.20(14)   Co-Development, License and Co-Promotion Agreement, dated August 1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as amended.+
10.21(1)   Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September 26, 2005, as amended.+
10.22(1)   Exclusive License Agreement, dated December 31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+
10.23(14)   Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October 29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing, Limited.+
10.24(16)   License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September 20, 2009.+
10.25(7)   12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.
10.26(18)   Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February 28, 2013, by and between Nektar Therapeutics and Wells Fargo Bank, National Association.
10.27(8)   Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank, National Association, as escrow agent.
10.28(17)   Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+
10.29(18)   Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+
10.30(19)   Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.
21.1(20)   Subsidiaries of Nektar Therapeutics.
23.1(20)   Consent of Independent Registered Public Accounting Firm.
24   Power of Attorney (reference is made to the signature page).
31.1(21)   Certification of Nektar Therapeutics’ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).
31.2(21)   Certification of Nektar Therapeutics’ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).
32.1*   Section 1350 Certifications.
101**   The following materials from Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements.

 

9

 

+ Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
++ Management contract or compensatory plan or arrangement.
* Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.
** XBRL information is filed with Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2014.
(1) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2008.
(2) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1998.
(3) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2000.
(4) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 23, 2003.
(5) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2009.
(6) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on April 11, 2011.
(7) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 10, 2012.
(8) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 11, 2012.
(9) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-98321), filed on August 19, 2002.
(10) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2011.
(11) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on July 3, 2012.
(12) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.
(13) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
(14) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2010.
(15) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.
(16) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.
(17) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
(18) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
(19) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2013.
(20) Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December 31, 2014.
(21) Filed herewith.

 

10

EX-31.1 2 d917300dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Howard W. Robin, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Nektar Therapeutics for the year ended December 31, 2014;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2015

 

/S/ HOWARD W. ROBIN

Howard W. Robin

Chief Executive Officer, President and Director

 EX-31.2 3 d917300dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, John Nicholson, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Nektar Therapeutics for the year ended December 31, 2014;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2015

 

/S/ JOHN NICHOLSON

John Nicholson

Senior Vice President and Chief Financial Officer

 EX-32.1 4 d917300dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SECTION 1350 CERTIFICATIONS*

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the “Company”), and John Nicholson, Senior Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Amendment No. 1 to the Company’s Annual Report on Form 10-K, for the year ended December 31, 2014, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.

Dated: April 30, 2015

 

/S/ HOWARD W. ROBIN

/S/ JOHN NICHOLSON

Howard W. Robin John Nicholson
Chief Executive Officer, President and Director Senior Vice President and Chief Financial Officer

 

* This certification accompanies the Annual Report on Form 10-K/A, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
GRAPHIC 5 g917300g52u37.jpg GRAPHIC begin 644 g917300g52u37.jpg M_]C_X``02D9)1@`!`0(!>@%Z``#_X6B\:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2 M1$8@>&UL;G,Z&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN&UP.DUE=&%D871A1&%T M93XR,#$U+3`T+3,P5#$T.C`X.C`Y*S`U.C,P/"]X;7`Z365T861A=&%$871E M/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z M06QT/@H@("`@("`@("`@("`@("`\&UP1TEM9SIH M96EG:'0^,C`X/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`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`R-75R0RLQ1S)'F978F1A.%9.04-X06-D5U947-ME9*<5!'-%9)27EK5C-,3S!1861,9$IY4VMW-3AY-%5J-$M$)B-X03MQ M<7`R=C566$1A4#52=&)W5VEZ-DI/>39O;'973T=E=TQV3VQT4T]+1EIA6$5D M=3=C;S!6:7).>$9E3TMS5G-F>5$X-E(K4S=B>7I()B-X03MD-F)P5'AZ4C-6 M,7%.=%-:-7!B5TEI,RM'1WHP,39,35)*>6QL;%E%1&1H5E-Q>5`X=CA!.'-0 M34]G96%R3A&=VA35#!);G56 M-#=F=C8K;5(X1WI%67%K82]K,35V:',R:'1O=$=I;6PP<3DP4S=U56UU,6MU M=G(P56-C=7!80DU,)B-X03MQ,#5-6$EX.&1Y9#54=%)603(S-41E9&].9G8Y M5F)63$M:2G`U8G$Q=&UK;591+S969S%#3DMI1FEG:U$A&26Y/1BMR9$141E=696%V>71'=#-6:&57.%9L<#DW8C9,9F%A,31K84Y. M1F-Z>'=P85-23W-59%9T*T5V1FAW)B-X03M+:'9G07%A2V]$5'9Y9G)*<&LY M.7`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`X=C9"9&56;3!N>F(U.&@Q M=7I7.6EM;#%!=#8X1%),1F-X;W)Z6&(S8T5B>4Q%-T]6;T5+8E5F-'EQ;U!O M3VMP)B-X03MQ0C`V,"].>C9J8E=6=$A"2G!Y6&)*>&-S1S5,3#EC5V@U>$XX M0R]:53AF4UJ5TAN=E59-U!L231H:V4W;D12)B-X03MY M4$-Y3#9W=DDU84MS2E5-2'(X4E!C,4-R3'8X;W9.;#%&8S(Y>#4V=DQI,G5B M>C8R234T<%A+2W!Q:TLX8FQ&-$1K,5%6;U1X3D)X)B-X03LS5E(R:2]L;#5H M7%N,DMU>%8R2W5X5C)+=7A6 M,DMU>%9I*W5F;&PU2#$Q518*VE1,T5Q4G9#1UIP3C0S:5=( M:3%'2$E+:V$X2R]966-L;S(K2W)B#)Z3D-O;4UR<$979R]D:V-$ M:7%R-64X=#9N<&QJ<4]S7E,<6-&-W%O;DQY4$I)66QM M4TM7-D%F-C`W3T]B)B-X03MF=E0X5WDK;T951G%0;39W,"MW,'4R,6XX=D,Q M+V5X#E4:34T:C%(8EI653DQ M71Q5C!D3#AH>39L2&5A:DAC>EA%3GAQ5'%K,&--3$IC1E5J M=7I);VQU<%$S0D8R5#=,16)+;TAY9C5:,$16,T=G87(K6$XY<$YL)B-X03MQ M1GA0*VLW;6$U,49B95(T65DU16U+;79W=395:41V4DXK3&-M24MR,&5$.'!V M261U>DYB5TTX0F58,3(Y2RMV;WAZ-'-N4EIH4F5,)B-X03MS3U`R844W8FY! M<7!P9C56*U%T3'1F<71J<&9P469723=V:5HW:5$K=D582U!Y95)J%96 M>%8R2W5X5C)+=7A6)B-X03LR2W5X5D1A:'%M;39B0VLR;UA53FY$2DEK36-K M-W)'DY+GI"-6(P8GI$6GA797)11S1T-%HT&AB5&1%)B-X03M313(Y>D)E>$5Z M6$5L3&DP.5@P2D0V:VI62V972'!8,B]L5VER2DY,05D)Q3VAA8F(S9&AP M8W5R)B-X03M3>EAL=F%V8GGE"2&U00DI44D)V,"MN1E='*U9V>E`X M.5@X=W1D53AK,W-21W!W5T)V,6IU3&5.$9Y4T]&)B-X03M9 M541G=69T+W-M:6Q6;G5K%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X5C)+=7A6 M,DMU>%8R2W5X5G!M5D9,35%Q<4MS>#)!039K;D95<$]U5%AJ0DY&="]R84Y7 M="])9E1T1CDQ96AA8C(Y349E>%IC)B-X03M657)R5'1.:6I&,S5J=D5U9T=( M15A01TLP5BMQ:4]!:W%7B]E,U9V.$%M2U@O04MH64U64BM+=7A6,DMU>%8R2W5X M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMP)B-X03M: M9#8R:3-$5U=N=VTO=C`R:VE1.%EO<2\W+VUO5FHO,60S<'5&3TMP6F0O57IC M96QR5G@K;&(K9V1.1G153%))1RMY5V="4$E62#DU)B-X03M/94YD>'AW<6U! M5'I"93!Q-F%28C=54D%K.3!2-W-W345:.%%&:RM9=TMI3%!23DYT2G9R0U)M M5S=P>$XS3WI45#!0565P25=93"]K)B-X03MI9SES5E(R2W5X5C)+=7A622]. M+VQ'=S@P-F1B,D8Y3$Q$2&)89'9E;SA"44U:3%HK86'A2<7-B M1SEF:VDP0F]0.')K<7I04U563'96;$)*2#%T5#A23$AE,6=05FE4:7%9-'$W M1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W M1EA9<6]8=#EA5TYU,7AD>7)&0W1">5!5$-2;S1T3S`U,FMV8FQ/4D-Y330T+U8T,E@S0D@W M5'`P=W%Y97DP;2]K=&MG9FIP1VYR6&AP,6E12D-#)B-X03MA+W9,:&%C4S%A M:U)!14@Y='-#<'1:5T9N6E$K:&%1<$)&57-6455Q>#9S>#9S>#=K-VY&5F9& M6%EQ-T9867$W1EA9<6MN;3=Z9'`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`S46UQ1W5(+T%,>5E6-V-4.%-K9&Q02&]3 M>F9&)B-X03M(:%9K;6MA2G`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`P65IT2&YN,&PR2EIOD4XC9H8E-W86Q/-&QK9S1!46A* M,U=25VM,03!I-4YT5AB M;799<4)B2W!(*W,R2V]E*SAQ<'%.<5E.43%+.&YQ>4]'5C!H5E=J8T]+2D5I M27%9(67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98)B-X03M9 M<31G145(;V1T=&HY-'A6:$]H9FMV.$%L<&]F<&9O-U)H1S!.,6(S.&)04&-3 M,'5R4EI&:&PO95--2W`V>C=D2S#$0O=T%J;2\V<%EQ-S%.4R\S>$0O>4]B+W%L M:7)V)B-X03M5,4PO04AX1"]W06IM+S9P67$W,4Y3+S-X1"]Y3V(O<6QIF8Y57-69#9M<&8W-&@O=T-2>F8X059,1EAE<'%8 M*RM)9BM2>F8Y57-6)B-X03MD-FUP9C%8S<6%L+W9I2"]K8S,O5DQ& M6&5P<5@K*TEF.$%K8S,O0493>%9F03$T6&(Q,&I22T1H=V1N3F0K)B-X03M6 M87%N=%1&5F)&6%EQ-T9867%K4&Y7>3@S6&UH=$8U578T=%`Q8U-X37,P-%AG M,%%B.39N2C1B;TE3;&5,96LR+V)&5T7=Z14)G)B-X03MJ:T5+,T4W1V@S<&ER>G)3=$,O M4%=/,71&,41Z1G`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`Y>FEQ4V$S'AX5EEC-W%C8V@R5EA4-UDU67$Q8B]!2G5F;3-(1TIR M=GED8WI*.5ET;VYI:#!R54DS5TER13@X=3=Y.&A))B-X03M$37%!0W-:5F5D M959-5EI"62MF4'I$=4Y'831N,%)R5SA45T19>4$V9F538V)8-FXV-&-13$E( M971Z4S,Y8TXV92]Q54,W67%G-VHX)B-X03LU+TXYF@O34D]10E$Y4'1(1E=767$W1E9K3-N;74TDI$1D9$1DI$8V-54S%*<3!J:C!W0UA+ M8U9A<$=+<'(U62].;GI4<5=R-EAO=6]E56)U>G5B,3%A+4C)2;75P67E:449V4',R-&EK2TUY)B-X03MS M<'%'.$95='DO;E0K66M6;VQW+S58-FUZ4UC5B-F9E4S)N-65A)B-X03MJ8UA-3#)K9'-% M1C!5:TXQ8GEY=DE&83%J:S114$=Q4%919FE&94HR>%9"-FHK8VXU;%&5P6DDU4'-"454S5E-M,B\U>'!U-U'=E=F$O M56ME4%1Q3DA#>&Q%:U%B-C%Y36-Q,T1C,4IQ5T-T)B-X03M8-&5/2W!U9GE, M,4M44F1E,#8T.'AP4$YR63`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`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`U3'1B0T%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6 M,DMO8E4U3#905')Q5%0T,6UV,&AK83!H8S!6-6=P36%S87)S5V]$=4U696%Z M-G`K9D9J<45L=EHK5SE);',R:4TP;#5B8U%R,V),)B-X03MY66-*8GE"-DTK M>&-I=F5H-EEQC=K,6Q,94Q1=$UG,'-L960W3'AD;#-!96MA6'=: M:%)Q<3)X4$AD45=O1E56;U=R9FY64'(YFEQ9"M4-VIZ=54Y4'I(8D1I4DE9-78S M06U"*W,S0553:4=6-#9F5C%G231,,6)F=E)6:RM+)B-X03MU>%9O26=C=49( M3F=&6G%B:T-P04HY<6Y&5SA654IT4'-*-W$S=DIR84M7-W1/9C%3-&1&85-, M,5)X:SE.>4]38S$R86Y81E9F1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T98 M67$W1EA9<3=&6%EQ-T9867$O=T0O,E$]/3PO>&UP1TEM9SII;6%G93X*("`@ M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO7!E+T1I;65N7!E+T9O;G0C(@H@("`@("`@("`@("!X;6QN&UP5%!G.DAA&UP5%!G.DAAF4@&UP5%!G.DUA>%!A9V53:7IE/@H@("`@("`@("`\>&UP5%!G.D9O;G1S/@H@ M("`@("`@("`@("`\7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS M=$9N=#IF;VYT3F%M93Y!3Y!3X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O M;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@("`@("`@("`@("`@("`@ M("`\3Y!3X* M("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T M1FYT.F9O;G1&86-E/@H@("`@("`@("`@("`@("`@("`\7!E/"]S=$9N=#IF;VYT5'EP93X*("`@("`@("`@("`@("`@ M("`@/'-T1FYT.G9E&UP5%!G.D9O;G1S/@H@("`@("`@("`\ M>&UP5%!G.E!L871E3F%M97,^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@ M("`@("`@("`@("`\7!E/C`\+WAM<$7!E/@H@ M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q M/@H@("`@("`@("`\+WAM<%109SI3=V%T8VA'&UL;G,Z&UP34TZ1&5R:79E9$9R;VT@&UP+F1I9#HP,CW&20E,C,T45AAE9C4UB8U M0D12-T-466)Q=('8_\0`&`$!`0$!`0````````````````$"`P3_Q``X$0`" M`0,#`@4"!0,$`@,!`0```1$"(3$205%A<8&1H;'P(L$#,E+1X4*2\1-B M9*:YH)QJ*7[VATO".<839\KQGT*469<_P`L?)W$,#^56RNSH7=0#[-3%N73Q3_N M\5I#:X8U5W5L=/_ M`([.\[LL'Y`)ESDAW;$/DIYB&\PO+BEW082AX-2:%#6(PF:`4;"BTAK@<*A$ MB:2(!^J+;IN_5R7GX]5FFP]O&3WW($R$H[L6!,R,U6_=IV1* M)$FPME&?&C!_NFH+512J;?FIC7X_L[>)1NUOE(Z287#\B\>+?+2MSU85#=27 MU5G*W)C3B.J[GR1\U5!QUH2+D6&MA1)N5FAZQ'RF8IA MO9?B0G_MA_MP5;^.SY"NHK/Z=YXKBV_D''.[@F.QMIU1P9U[R>CRU+HD3V". M5T6'*\WB%:[(S8Y%CK=VU81^<35B_F$<&J%'XMB7=K-A0U52H;5-EBI5:I_Y M)N5X*Q,E*6Q\I'R%47=G>]#=J1?FFOQ,VN=GS%R^WYXK&P8K+8=3!BEJETS92Y::E398M)6ZQ M/G3Z:8F_C"Z^\<77J=F_CMZNL' MIJ]_D8&F[&&V)4M2=!0`!STZ#B8HU%#ZOE].QF<,_1IR.!Q[V5,#+DOZ99&9 M"_-O]VSM/1N^U9^)(ZC%2A46AM.<[-K?H5-AUB_(3\CG07<'O.O9@WB2B^.N MAI9R?`@(#G^LKHDMH6S6#!EO/YE992S4G*K"+I&B+5L$!1/4:F0"O=='6Z1, M,H3-"_32J9IU.I:G+:A7Q'O2^%SHLHR-*$Q#MP.C;5JJB2,D]=/_``A@T0;C2H4U M0M5J72FVOS19NWSJ?H`^,ZQBMMT0<`7,CF.)!18= MH1A:4(#Q&%+%$6A#94MY(20?9=QN5W9-W:S5DGJF.=:AQITVQ,^,RSD16/R` M=6S+Y#I/%[@ZMM/F?G1SWU,.;:*KB4_'N,,4K>H&%$F(Z/0)GV,45CSN+SVX MW`^2IQQEJ,/O6C71@2;&5%";42R'1TTZ;4IO2FWJNIO.F=OB.G_RB7!U5RQ" M:O[!H(CY7.(K(B(!S,P$PIY+W:7-6@"2 MA`9(3X3?R?1T-`JLGXQ0DYI>7^5\/KT>,,Y-W_\`(9WX^^-[O'Y1:ZM4A2]2 MGK`I^,_'U7;ZJ:M)E`=,M[VKRLY1?$P3FT!/'C!N[F1(ZN!C$E=/P\7"N%R0 M1DY]?QDTQ&U33KIHB7?4Y>8;A1P7#^-3IDU>70I*.:?+%;/9C(%6LDE)6GIQ M\;Z/*(;1DW+QH&E+=+/=4U7RCAZ#)'F"",69FUW)5$DX>;CEV8MTX:C-:A?D M5-\JK5X1+(%Y#^4_I:T?D68/[,."E/CE[.LGI*@>%=D(Y%F/C"?\N[1%GI,W M M?R>=`@^F/D2@DD^6M3E(I0UX2J"\Q*]H-&491)1N-MY&VK)]+-W9 M>4*(Q5'5\9>F=]W>KS]3OKIYY@JI44__`!ZDTFW+6[G>,'Z(:2Z;M\'\:,=Z M[ZQKIS#K>AW+,@O.Y*[;C7,:()D(/"#,O)M?L1#Q=Y%BDA%!4B*\>?)[.HT_ M**!W3?19@HAJ.;2UZ:7*U0GX_.YSMY99?,K?M2;NKK\G]S_`#,Q.6SK4K'^3I\'"4"P\B\.8_L08ZI` MG,%VVSH;'VCV4_F2)NB0_.F3B0KZ_@_2:*ZL=MFVPD*/P[9F*USH%HO8E/R2^>V!GM75'XM:->0CI:"5_,%66S2`)KPI89`)*_ M646@.\7U;M63DJIHJ];ZJ^CIHI^M1=.*;NUFUWN6<&?*#V+//DX[',>B6Q.\[[WZP"_$'\ M;_L:N5M92`M"7D!1E>(JQ$'][8()(>.HX!$/1OX?S1+A@MMLIZ)I2KK4 M62J:5]E*+U\`=)7/=W37R@UY9TQUDL0YTZH"UM3HGR/18-[$86[@;0TX#^OP M`063D'JA)7=S]QD[PT5T_%^3H]U0\\2\$J22H:WIE^93CYD^].QJ3L^`4IP( M0$[6)4%'61W;U2S?QN-2;5WS359,8#:P?\,ACLD]%JV`3VE7BSP"F&ES5,`. MW"%V^C]?\8M%-+3=6&U2NC:SX>5[DC?)!>W2IS@';Y&N&NT2='5]&N;6=UL* M[;T72EHM+1\E"00T$W-2>R@4C*0Q^('E-A!`:&:+)I/D7";UM^L0V\T"A+5H MJIEZHF7:.S1"4BN7Y`>>1'Q8K3SN4Q>"W<765(QR>.'G.W/5>+Q^KIY5#Z2' M:\&>1F%.FKGQ0VLU?HRQ-J+D:.S'1NBY39+KM=PBEZOIC32]WE-*;LBM3Y/N MOH'\?'3U72J=LI3\H%1=S:?'S7$G5A4"$K3^?VO839S2UEMH&-C",!U8$*K< MRA_'6W[04&F?8#J[+#7>SYX[.2*K\[\Z0K;Y!>LN7 MK7^5JR.78/S[">2V<`=PGX]8)T\\LR43CGR+R2W)(=WAE%2E["E'DRVVD[9@ M27:"%5)<\$11DR#QS4>R%5*TTM4)MZIFJ,.VZ/T358ULNV>*H9Y">K)`>LFQ M*E'%(EUP1HB*Q22/'DF;>%P-B.^?9(!#18*03&O&NBL*/1T:DANGZF3&MW?Y MR6HY.U6,/$VMM,^LG'/C&?\`R(R+J+N87>?R22:=T]\=MI1<;+(!2^V2/ MB%L/9=*(O$'[_P#<8LT+];$G3(>AL&1=.5!(-4*K1&\:I7$].#>>=^:^=Y\UH]'HN`_G2XZQL6A=GR+=8WNRI^KKYE%459#/6X)"0$K"L"Q#%6!XZ7K5K':TK5N-A)ERE&R>_ MC0LUE"C)8W[NMH)2DVZFHII4M)OLE+O=E=)J]#T M1SET5JK$882=B;%&6DVK.\0+Z*R./F`$>4EF[121L6K(8W?`0\D&>"W+%;33 M?454+6T\0VNT2OG^#]*F#D?DRZW^1RW(-\DO>5"S[Y9]?C]J*BV'-*M$Q7WC MVK>AO)F_LFB`LSL!KL0>5P8F?NXF2J-"*;-\>FQI5Q?)G\@<;YZ^((]?-]27@Z4]2.^M6?25@`>3X_; MTL?1RJTP"U+35.@Y#7O)5F+2/M6#$6W79_8JI MIU5I+4E$2XW4WE8N="^?S_3O4_,=G3'GSYC[/G9N"6`HY=VM)OCAJJIB8\?' MJ^?E"58(5Y:57PQH5&G'9R.212=-`SYTP<"OL;)_ZFN5:Z4RXI=Z%C&IOQE- M]=R@L>ZY^3:-?!M9/RCR?O7/"0XJT=LF[9<=Z^;O]]' M:43E+XL=OCM)U=%,I:(IA37J?$O-O"-CJW,_E9Z+Y\^7XY2]]>(,^'7L'Y@@ M$R\T#1']%S3??14(<&X5(C]Z:/H'!A#YK M5%-7$69Q<(GJ*/5^`<#G\2"/8:M&Q4:2FTY(O!SE"TX"^'NB1T2JFA50[+2G MS=KYOYX/TKAM2^@@5I(%AS@]J-8ZFW`ALY9"5R^K5+PDL+9O'9!VT'*O/%MV M39T_>N4&VR22[MRKILMN.9DL`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8` MP"C?>G$PKMJM(*"8V.>I.WZ4MB(7QS]=L9#CI&4K*V8/NZ\"F'<7++-!TNCC MMJ_>,C\3?OF3,NENV44\*UL%;-OALZ>GE5USQQT'\BY:V?C_`*S+0CQ* MFF//\8AMN6/7U:%!Y6O:DL>YV4O(*.XK&MPX1LN4%QIN5--PS)39,6\0'NA@ MO^HI=2IBI[S*3>6E&?,]?:?P6#>P'W;Y)7H-*OWO65N\HVO#5V-6[E=Z;7YO MI,]1)H+[^3803]XM;$ALKDC?W9']J-P")#1FX92!!+;U4*?Q-.FTZ=6^9<\6 MAI-C=ZLW-HU?'.2XY%(PPA*NGD_%Z2 M[65CXLCHF6UUCB8+1?Q/848\1]]5!5Q%IA5+.=3;G'4Z>]2,"#D+W>EWD4<&!0Q\F>'+B2#QH7T4 M<>C]6BXPG%2;4PYB<^^YRMD'^SW2%-^;^F^>+$J&Q8WT(X6L:R_ M9.0K=9LK)!DJKHU:@N-;"[)V25<'VX-0/HV<;Z(-]%!&SL4[&_\`4=YNJDTU MCMMML3$\^'.N)G2_R%TQ;%@:S$?V]U58O5\.DHR&^1^1\\3R4,@O[+?QA\I) MBRQR00(P%2?>GFJT5TD8MX2CCT6U%DG^CD36YI:_I27=2VY[S!](]\6MF'K9 M@]Q7WUR=L.;!/CEFOQ_S.90&$%:HL&5K2B=OI,POH/,T+(E#R(V`+#*CT'2: M#4I]QF+1S,$B0YL]\CC8-2B$K:E5>^$[84J_E8CB#?$]U!(;)Y`?]<][->BZ MCX6GX*RJ3CP_GD)`+8EW-E"CIP8YW\1W4M8CKSI3CSY"W//?'_0LPG,N/4^9Y\C M=E3BI/;1W4VL@#25H.IG'W3T?%S\7D?^ M,,=TE%8=:A"QH/=-NHSZ#B#$=5%&*VB`L2H"C<$)'EI*>]FBX0-JR'ZR/QC& M_'23+3;[*W_'^#06JO5%HA1WZD;SCXT>GJ\OKH:X^`^Y&O+$?ZTD23^.YI7UP&]D>(+BMZ\IT:F,9UD,NZ*L*Z8^J-F!XT M:;R,4A$'BA1?UTUW^WRG\D,T&!5?7#AHJ8=@ZYU6_,DNR34>WW.T>#!Q=E?Q M?]`VK=4`5O3NJ2V]R54O60SL:NZ5DM6CO;893N+.GY&OZV-WKY+%-RE304J2 M=.!PY.$M2Y$6I]C>.T]D6A=L-ZDE:F'ITMSX-QR^YU"Z%JK>]:!O&D$SFL84 MN.G[,JK22[CO3&D>WL*%FXCJ-_6WCYIZK^H M3.Z:Y,*S3X.=]X?%X]N'XE8K\82-W-HX]C-6\^UQY=F]=J%FSI6C)77\FV-? MP[\FPY1'62_L;UGJ/]FJWHCTGXOL\)^-/47(VJXKUQNW$\SO'7@*N"@\=INT M2=$4V>Z[K1%'=)4)HM]#LY_-,],%4SG^SF\BQNC*A".1`5T'1`D";98>X59CMF#T7_4%?(U7]W39I84<[\N/:Z6FPN%_MLO1LN:1ED*C1F*$ MWDFD.Y:110\P;R(29\3!IK)ZJ`R0]X,>$-'8FMS2U9TJ.]W[S!=JBN?9I&^2 M(YS)U!9[3IPLA69:HK!LAQ%7L(7M&&D!K^,Z>R4*M+)@]^_/(:Z0#R8U^Y'+ MF1$TGL@4\9NB2C=$9;4RE&Z68.85??$;U1#@U-&FE3<.J"7=&Q68LBKN%A%U-&CD@)C`PD5%((C$6@=-H'7#C;K3E MZ5J:AN95\O3S'6#<[O\`B]Z97OGJZVN.>X!O.$5[C#QMAT/7TQY^"7'XS/Q^ M%K5_O.:PD+N:19Y'2Y*-NG>SD8[;N&WWATN1](*)IAF8,15J$JJ=6G%XM,P[ M/_!BI/\`")7):'\]U@)ME\UK6B.$NC.+-A9R%HFC\L<]`@&3!S;*IAM)1#$, M5CLC0H.7^F.>+(9*P!Q'REQ$^F[)(3V53QP;VG1Q:.*#F9'>-(B%F\B=.F;9FY MV.M]D?R=@JKF;1]2:Z0H2P1Y!/A8Z%81OFSFZU.^O+*X9Y2N>'7'6U/-N>(W M%+5D/\.#Y*10"!3JW6ZO(V`=E%FKYZ/C"+LTPT\22:!EDQ*X0'6KM4Q4U M#XJLZ(ZRNKEKY!Z]IN.=86XE;D7#!(+;"J)7:2NV^\A/.W:C= MEZ1W^H\4S46(.'XFMPE39+Q;;>9@VF%?%+((?\85Y_&7MT5Z:ALX7M,!35@$ M:YRO28`(.;#*S]=6?O(>3=G$M#Z9Z*)D6)!FT1#BD1:>K@-?UJN+ MJ)OE\XM/B39=7Q^.+=8_'&STM9$!_N"VY5EHN%-H4H3_`(IZ5M!-H7L$1T\E M;#]E[&=MON.I'?:4^,///TGK%Y[_`-YP151JM^9-=I:?V(:?*A#OD MDWLYVP!AA\3D]?-R MH91ZE($VYAZQU%U_1IB_ZIV;3:\U_!B)S\^J:;.MD4QAQ-E"XF?4J]S=Q(A0]Z=XV^8G+ M*?">VK+B4\=0I>(?:$(2/C<%4A+R-OB2LA,I2]$PBJHY5=_:X_HBEOLSW8N? M/?5\%=4JE8TJ,_(.;FGPR=/Q2FIAQ!4WR0'X)\>4U?RMBI43R@XM)KPB%53H MT_,S.EHG>;Z6(>^Q>0;%3#+TX5B3DBR'EWC#<<18JNVSX:UTRJG1-2WU.&UO M$?7[PB`Y2-+3+[Y$.9198(%K;S?:11Y8 M6Y-#'[5#>7.%3*C)5GNX7"$U'6WJ8RJH;;NVJE_=N:+U)\453=N]@16_^KS> MMKTI6E%DJQJWFY-M,(:SC%@2.7,Y#*K@(6'$+!$&"Q0N&8M8IK'6XD4-T',A MSIVX?NF.GNX*IJF%9MRWRHLON4TF/P'MQ=9=.T-S=T>THZA+HO\`Y]Z3J:M2 MU7'+02H6R*>:,M)@JU-'K='D)T-LY^*#/'"1?TGR86+< M\@86=6'R/P_G6&R&J%HGX)7OE MI4UQ33F7R=/Y)7EN1>,PJ-1:8QLE=;9@_,5[$A)2-H2/U[NF:%.`/NX<<2!N M2!B1>>_K'[&M:FKZ;51*3C#FUN?\G3'GRF^N8O#K3C75O5<+Z0(3(>B,A)>( M<\"J+2@S5<6:8'-7X\7/ICY*]B:[\6Z0W6%'C/V M16&#?%+$QWQ+H?%98UI$)?'OX>R*&.[:C\62BS_PJ^LXM:L8DS*(O3TE11VC M,E&+/AS6OY3/K(*LYE*5I*==Q1FV0T%M6K-DV+-FA9J^0 M_`0:%@=2AJFG3JB;SAS"LHN1ZT^$,$C\?M<\C>7V[$7G1-U3&_\`GGKB*5_Z M!EE26+);1,6&BY%Q?]ZO'3T/ZQ+[1J0B/9FT:'_TH\][HQ)"A/C&)62XCT+K M^IN+-).GE))<=))X)?%F#M:==JRSIBPPML">X>;^>Z/L:-1^O-X2WCTHI*-& M1[FSXH[?3"7_`*)\1EI1M-X<(4;;JP0F'&);FY)LA^K]IG4UIBVEMISS'[7Y M)G^,?AUY\=W),3Y@?VG[<<*[]"F-5?(X;/4]6R`**A>D+E\ M/]#UC/3,'FD6A4%?R+EQDW+GI_\`>9*QLZY!5"2RB8:9L"*(,)9! MNAJ_Z*M&*'I]*1C4NSKDC&H3RM<9.<`1S&?;L7(^-C(T0E;V1:I,1-/6RF7# MV:3CS48S>#&N_DTT_2R\D+YYF3X93D.VF/02SJ;P\>[K5./]"WAS78@$"TUV M>Z6&=B\XH2:F0OVYT'"2Z'M_"29H,66%`B[I\W_8:>N<6Z)KSG_),M:=H/+' MM*`1)O31P36]N2*^([6%JKR^/N_3*W/9@I'Y2]D,)103+1EG*R0=^]K_`/*( M&W!*.ME",J0AI;9M'W(D6GB)\<1]\%([W^0*]Z1.?)(QDNT9'0JO4;!C''=A M^!&^Z4>NRM>+*IZ'+518Z+C\0\PZFFDV,3FKWCK3_P`73AMB1$HKHNVA;,J- M:5%+W>5TU-2O*'X=8D.X_E($,&W1\4K2)/DS5>@^L83")]Z]9GEV%R\TUE9\ MF.%)E7G@OW4#6* M4C&XRQR\<+;#HXT?GF\-'F]5T!-.>5%EU_RL&/BORF:3@JVA4*HUM.K)-R^G M(W%`\$NR&R6!F&-WP?HN:1@JO:F@9E'O%8[KS-/1TY1CC65AF/JPMU$9)-OS MMVVHKIC+A7RFG:)MXV^Q-W<9:_8[&M6 MG;:NZ`72'(694E8=%4G0OM^)+PJ+F`Q&S^9:*G;5%M5)$BK8LV,/I22 M';!]8^+ET>;1P7)&PLNV!BPH49=+<7VJJ7LK9->B/RS@)W%&9Z)4/*CQ:9_P M.JHJ+G\C<#VP&M)L!+S2,FY?&=74O8-XX_=.XS))4^ M"FQH\-,9<9F5PIMN_DP;),_E"`5U-)9#I?5S#]9%8_=BKX?$+DA$\E(V:T12 MM`T-J>V4TKN+/> M_![9Y\F#.JR[*O+-I=Y!;IDCBJR$.A9NQ@BT1<0FX(M=\LC[8R\='V,==2H!(VTF;AIWRKX5Y43;Q7@;C'/D7A,F@DWG3 M:LYL.1@E;\^SXN',.!S$DHXO:[K MYZO;4J^I+5H%]5Y^>/HV+=EIK:T)`P\F0E-J2&L&3*G9P60'PJU#+!N#96*5 MA!B15I9RD$ET-1CD#DD_.:P1N$6E.?#I-^.-U*=XAN?.S;?GU#6=/&B7FOY:SQ!NFMYLALIIL M(E+2*0B/DCE53B+2E?2M7$V]91JYNT85'+$AYR,E2#C_`'9@UJ6EY#T8*BD+ M>N6W\-:NDT?#S)^5:/CTX![-2D?$B2@V1O!=,V6?IMWA9[OR+@\J]9,.F=[` M%^PQ6(2"N_V@[)_;9!I-H<3%3EF9BD??-V# MIL^,@3P(V1!J(ZSM&#GAR5\AEVV#$/CRB5].XE&;HNLY"9K:K]B*:"HO:?.% MK<$=0]-0&RX2F[V\3C_H.?5>$@EFIL5$]@$S@$BU_(80RR662FOH#5MEZ.Y M&";:6)&5!M32Z7H2HY$D=SM_`X6[-B&@=P1'B.F(F4IAVW^3MMN?TYZAZ':" M2E9H7C8T=LHS<7&T0;M[YYHB5<7W78"\[K>5M81EH/&@E.?+9K]TS1:,X)*H M%M*-XS)F4H$RXX845CR_@0N%%\-PX4KJNS@D*UNO[7YB']35'9EM0F63R%1_ MEI2BKMD<8`05HU.=BS2UJHCK.T@0]ZE#B"M*GZBDUN2H@(:QED1J55JD\#(/ MA3TR8$23AQ:\K.$G;=3,*=]^/[J/L6S.I`O*-55Y:44A4]L&-=,JW]<\.!1N M8I-Y'QY+:NJJ<"JA$G_#$)9.;>E]JQZSH08D8J9"V=-H/'#0$1=F!AT4$1+: MM:%WEJ=[)/&^Y-\2Z;L2O*D[S=VAZRMN6\(D)IYI)XX'0BBMOQ\5S9`NE8PW M*A1VST4`GZ8B>MX3*$0**05^_&M):("`F4D0C(D(O3%M77JUTXW,4K9=YB+J#WH>5.)]'V8@RB1")<)?-Y_B(ZGH*]V3H18`VAU^:B"W11*8LHVE!6]KQ MGV":A350S^X@$U]LU8$BM]E>BZQFD2>L?83J>'S41^F3%OXR]'2IV$+,VCB^ MRB.;K>(WFQHL0^34A-0$!*">9Y@@6NF'\MV-2L",X$P8Y-'[ M31ZR@;R-K09X9F8=KM+UV<6)#WH9V##/;%C#J%*MWLL(P"4F(R!)` MJ<=?+#B_A_#1'P[Y5#L.CKEG:=2B25DIV'VDOY'XA-T1K)2H.:>I)_0\=1"* MF`[E216Y)]XLX!@8OM]GCU\!Q;3[JCHZC9A600".[+[*)). M4?$W`YYIJDLX3P92F5V]TB.A'R#GB1P!7+GG4X'N>R-:))U!`W]D1A4+)XQ? M\*Z)L2-EIA-AHU\V@I"*P_E2[2,Y"L@LR_1N00)A%R$M5DC;=L+IWVO-MU&W M_99@KW#/EB4C('0-;%<%BUC1U[;"I`;D,I$A78NF<=.V$VV]L_X+XT]ULRM^_[CYU9 M5S(@$SYYW5TN<@3*"U@,7:W#7NA&PTMF;=GY!&0_:. MR_\`2R5RV'J#+4)/G'7GR=B`?D4ZOO/FX>:;U("B:K37BOO2^5I6;7]-3(M*3\TN\^Q\9Q\E M"=7D74!LJEEX3%A(@9LL$M"U@\MJV1VVPETDL<("+_`&!`8"B)V.'@ MHN)2E^A-_M(T&I((T2VES,-.Z$C(["'0Z1"I5)&[=P::1APR'F1QS?[>8#:OF M3QHHH"5X=XG>UDWGYP5BC/573L]&DX_#K)'%E18Q8DFN^NH=&^F7-:DJ@KDI;:8[BWI.N'$@A$X#*1.,GW+4!<4X)63*(8LWGG@ M6);1R5`FXU";26)2F=FXFI;;=+Q>Q:85WG+V]E/8!8/-9R#M8W=,0HN;21&T MX1)&P28674["X*[W%,6Z([8XP5CY82(GCMR[!MHC(B*28)Q.@;=^>9B:;6C\8*$K2Y=6(%(_/XA<\:,U;>4RG$6*1Y>4Q5 MK^UA]A`G$+51/I0TU.8JS\),%HU8$@U_5;-PC[[1A3\P8?E2^>M>TJF82\)> MD9I$]7?-W)\B)+>UA$Y()L^[+IY:KCH>62ZQ$#NNRP>ETE[&#QD?&:U6@\F2 M>!9PZUGVNFHD<(BND_'T#26TRWOLG$+KU<[6)V-?(K'HG=,5IHS&8A(E31N/ M0E_):^MZ(RHAK*Y!3"EP,)$VK\.F4)AJJ+)(^QP+(9S((K-2+U=H985Z0AST M;*"-&FTWYQM/^<3WDECF7KI_?A",B)54)JH2M@T/!NDJZ9$I8#F&QRL)NXU9 M>H'50;=LE&9Q&7KH+Y(H[YL8$^,Y(&7#2DPZ3/L`0-1ARDXF(O\`/F)YL5GV M%UU*0`N=Q:96I9#G>3]*HVM&)AQ[(:\I"L:YK8=>2,9F$&Z)?0.$Q";&A76DI*MC9P).I%'!6DI7"4.9;=LK_`!'H[+0KY&I2*JX4XN.I M`T,LSRI>5K(07EMTUM#X')`G2[>R1H$Z=D[G7SR*'6LAIV;)&J\A\?LH]XH1 MBS:&IRY-Z55`B.F[C$M8EVZ>*AN#R-OE3;EX2?G\9YTF4ACM?47,KNM)PA.H MH/6CB$)M:^J1>1&--2J#-W+S)VQJ$-MHT\60C8Y:.%VIR0*QMTUV"N0TX4Y: MBVS2<^3P2(P^0"3CYX7AMB?)K(V-KP$^Q&6=OS/YUG&FH75_Y M%VY2,E*H>`FAZ4'"$2:1>;'FP?\`(,1X>:EPT'3O.TK.-6GW].MC4J^^3X59 M)A6`Q:J!TBM;7GFT;=943!F#_P`EX:)VB-JB54G+(_*@RM4C M+<`NI5'2DJA!ZW#^X02TAX&,IGFMFB8R-W'3V8&&QN,*,X`:&O@0R12Q$W#` MP:;3W[6SVZ!TA!YI3]9(/9W:E,3VY(FRFIQ)N!"B:VZ`YQI&1BS M*HY!1PZ*$$^@FQP&JVU\9(;Q]=)^FOJOHCN*J+N7AI>:;7L;A!>VYQ)Y%,X! M"*8EERSF!2J[2UA#$)3`H8M%H'!K_GE-@`T,6()#A<\DY8A`Y8E$!I=Q$6Y` M+$G#Z8S,(9*"VQ5_/I8D>&.MXGOWXDAF\_D]7"M;]@T!C@`1-X;7'0D@@$M% M6'";3^WR*@)."C!IC946C"9&/PU\>\-^'8S'_9C*)`@-:.A\_!023HK1]$%3 MCNEAK/'WQTG)9/KWJ\]S!8,-+*#',CK@9S!V1>4YB`EN,UDDF?T'I0SZ,CP) M8GNB@-.J-UYU(Z=$ MH3]U&-*]WM",^Q+:)LJE`W(ZG2UDZ"-T44T`/)1AR_]L%ZBP2[-" M(UV)8E-)8VAC0J.E=E[LS8)H`C#_`%4AWD[,,B(-DV^?<:<]W'ANW:)V]8+Q M\U];,ND9C;L*%US(H>3H`\K75PKG2@MRS`7(V*E-75>@-V/FRLJ9HPUO'+$T MFC=)@#Q<#!!@#`&`,`8`P!@#`&`:-,*VA M4_*5\8EX7[R^JR:ZV+!O5")9JT$3-.+2>&MS;D:Q?M1IU1D!F,@3',Y"T*CA MQ-RSD+!HWD08*5'!SU_S]B.'G+=$OK2D5T.8+Y[9,L9O&4B/I268-FY34C"1 M];OW2T>;2!&,:%GL%$!HPZ-H!DC"XL(#25?;;!AF[067$;?/W-7*\5GA[MEA[(Y%YSMZ#736ME5B,ET M(Z&F(FP;>!$R\F\2E,T`QNOXD%D;9XU-MR46)"@-6P)J/4A[P!JTO[OS,`5*J2.2E4"Z!F2GR)()?MLIMB^3YROAOE MZ:OC#^05JX5WD1LE()"S&SRR`(<^2.U1[1\F],@0,O&A"3&859XWB=A7T"(CI=.KF MNFQSJ+BKXW;40@&N[R?6#)/SV<8C=Z6J,8CU]%&"VLM<.WS9V0'!G8X)<1MV M2S''9$V6?#:XF0`5_%%N/4CL-FL&LH>Z*''D>8!YA7J(S%3L-22:"/N,:=(2<`Y+.C>[P67Y*%V< M_N_,TZ*<.H) MM3L"+"4PK^Y?;6=S^GVL%KZQ)2B\KY.8@``:)6-*O"X/<=.)`J9"7Y],STB_ M\="*GD/^)N6U^G:ZEU5$M4U;LJWJR434=V/*`];NU8G-REDU0"NHP-N-A'+" ME(^?S$Y.(>_MQQ(Y.0D4M)GVCU\Z.JN7`36MGROI\+6\+6P25&*/^.J?UM8M MO0N40&95.[?6)+9=:\5Z3E4@@\"?K6B-Z/GAZ,SX1:#L)3JL5MH&SMU)["2T M0_AU)47)\'O'?';[9<)JLO2%QIXO:W4^4LYW^/JM(=&K=GDK%Q*NRK^(&MIU M,>H+*'P6YBRTV)6]`B5E%35J:1WH`DYF9HE*8FI8.\VZN$@3">PZ0323S\ MLY&W&(EOW,%&JW4=KBHN<&3)JX@8&*"FK(LP^P)*(4ETU:&HV^WR2&(@Q^,N MYJ_)"H=9O/ES5W#9S,I1*=QW0K"T0S&<]0A9Q4TJ5GI/VPS_`(_G'[06FK>FZGYV&2HL!>R-DB<^T.)7,; M5MJP[,-*,(ZSV%Q]@\F]OS&6FF(`$U<+IC!&AAL):NR),EXVV+&2KU\,S/R/ M8C24\&"H!A$7).FFK,@C%R8"*2 ML;X(/@`)=D";6/G'W\)ZFA*_']S*]!G0IH1;%2+5\0>O'*X:GTWV47L[1!F MQ','*U(N8O.W@S847C]JB98'L6U[ALB;R@I;L]CR_/,/=2.P+:GLDD4ZDQ(% M8"M45P+EYL_N+5E^D?@K%@2+HI+!+?EA+;+QVEF6G/&G.UA$9<<.PHLPDLVG M;.SC,LAUAV5`):VGS2NP]2*R>-2:#R^/FH<^-5H`#0J7(1-Z&'SB/CT1\S9G MT?5/%`EKV]9]S(\['9^/694N1;^^^;HMM&[+\MHF#;=W\\B)6?$G%D.?#H.7CNY7:: M0.<517]"4@#`9`TFX:YLMROJ385 M$3UC<.JO3GV&1F25]8,\).'%1-WE\")+-9/*9(>8W"XFR)8A+9AJ^U69S"4-2XFIS,WMLK1B., M+'!AY[RGQ>%*R68VDD@-1>-)U/W;*>WM8[%D3G<1G=G36'0X[8J$,K=F0 MGJ<1+3<_#0\>:^OR^C(HY3:RTHT,BR]NUEX+^#.&."N9#.YA7>+3H2K());L ME,K16\KTAZ[_`-ON2MIK<4657BUD"%DZXG\T;[S(S5Z&Z->)2TB;DHR-,#1\ MT]?B:G[;+;'D2%=E>\Z&Q5>:7AI$Q`0!('4*K;]P3!S!!NDHMV#2>B4XB#V9 MGH^W*FYE#[!D,'CL?^KUZL\-(*QQHE(6HIXU!3MW\K_8C:P:,XY?^31/9@#G((W5:,[ZRW$]]O0AV;T'\;=+06`RJ>3&*U-7!=CL$CTB/]3V)" MXO<0.0S:6WLG'9J;?6RQ:W]'G,NF\ZG[$-/GDX&-ALLF6K-!")2&1,7POU.? MVQMQ;;C8QUAH?&G6KEBN0Z2IKGVP[;A\GEDQF_'H-V0GT?MRIZY";6U)*[)69&KBD8VQFXU(:3C3`VP$3:QT>$XAV=\7]XW(TO0)P-M;#8'<`97&9S(+>3B-E-Y91/2DYB928*<\$'T.`67%VC&W&Q2OG<]T@IZ> MQAP@4W:OXM"9<8>L`T4$#A9J5N)4-*T]UT^Z)(1XIYM2KTY6N\&-/@\DFXZS M3,I,6=:YRX'EE!68\8"L7^/9J],Z@0.A,GX'&LON+W\\&V_B7HB$6GQUBZGZIX4MKEQ?QF7=W)CD_,5%S1]+2$I@+4TYG4_C5H2WQX:D MWK4W.(A`QU91\NZ8)FDV&B#.#"6`!8(W;(@"22.SPH+>DG#EZL)+YZ>LD;0[ M@OF"#F(_(14-EY,]%&U;,(V7F=TW=/WP433Q8H;J\&/4F]BR#5N!A)(V7'V;2%5X217@30#6M6+Q8W8KPCS:]D#J5CH>;!F/)6A8@,2)LBTQU:QNRF,'2KH=/`]/"YP/J]D M<0A[=N!<[M(JV2?C?UJ#K3?+D;F*D^6@X.KXG)UIG<4#H MFDH1-R\CL*8R^5MX``:2:/PAT&B$XG,V>5'6$IE48L=]%(A%]Q4,V*")`-%Z MO]XIO]O!MN[PV_/>^[Q),U;0*DMZ9_A_5V@,Q2YUM.QB:$6R"1K M3MLUE*9LD05W<2,M)$'GK8S^<)>[.6#/9A^A1;M@CXY7T9JET`M^Q8#8;0#SP(LUI$48(4C,Z!RGQ>'1J]+/%2(L&<;%#,:GQ M(7-7Q82HP0;!+OZV35_#I^QD(_P[R_%XC,H*'K9RG&;!A)>NIDR?3^S#+P]# MSUDV3;Q<6Z-&9D0.)+/K%MZQ9(J7:DFYKQ61[CDR.@<8&'C@E^71=%]D;/-. M3>>[$3FZ,UKAG(F]D6(YM><-'QV5?HI%/'E#LN9'9AZR1.HM-&SJC1S2".`# M9%".+()['5!.TH77-JA+YZ>L^]R/F?`O,K/PNYUCUCNY$81K%%2=EN@>@#5D MB_X,J3K:L5HQ8I>SGTSB#F*-[-L`8@XBQH.J5!S"0`#^Q8*4=L%0U/WV6^=K MXW/<-X2YB"DX\4"PB2!MP'L55=#Q5LV^P`SI_"9:2GD8-V['6T\3!W1)!LT, ME90K)K883*0%C#]R[-DB6V_T\"7\C?CCP,-Y\>?)W_XH\4@4J72E4.GM?*-' M-T7>Y'Q:%67.8I9LPCE:C5K&W'U4P>S^#Q25#-JW;19U&B05EK&7`=FG^EP- M3YXV5XM?FSW,H:X+YO/K#C-I*#IZ MU5M*&2R7NWYDG"[!WD<5_$4-#VPAN).FF!`)?SI;P[F,5^//DQUN_P#']?R< MFP>B[/!-0)*Y;M?1:-@;G+:'K/!0J*.+%WCD'$2XTDW)/F$2%AD&SAF-U&ZL MFXD4BR#4^>'A;8)KMKG>G+TV\WM2'>2G;6N[.JCSWT_*`OT@%R)19"R`'TCI MH3Y])(E"XSKZ4^GWD1]L\V!$1FSQ_P"NA)CW\C6IUR;1=B2$K,3T:D(^:F92 M(F3J;PJR[.KF:-I`&@RE:-W(:5P"8QL]'FCN!JJQDT)`OQHB0,=O%C;%^_21 M=IBR_GF::%X-Y=C6T%TC4$D$;&5['ZQBX>-@;7MX3$302EWGW"J6UAQ)C.T8 MY:B\$=^)J@B-E#)623T0:-G3QRU9,T$`U-S?,[+?/:>ADA?&%'0]%EO6`J2U M8805K9(K)(9/["8'I>'KF[]+[U&3XEM*]W5@/);,GTR1F1?=^[$IQ.(I[[3?.)+C\`1ZZ0Z5T>S^2W&<@KUM7"4$&W%"+DB9,9+FH:3: MV8L%==$]#]`7&8:/OSX4R*>.'DBYU5(GQ']VT;TW'?C8Z"K:Q:Q1&+ MK^;:`>C;?L4`1&(M]MF<3NI>RWA=WHPL((B*&I3U2U+M/*UTN>ZCI;L2!&N1 M>G:*BEDP"R:U$],0[J?FF0M[R"4.4+UK('_2L8EY*PI583F43$R8#,K`NT=; M5G>"C?OH6,O954E50TGL('&ONK(24XV:=F[VM"B,4QB]F\GU,!N@2A5Y/EJ_ MZ&NN"P^Y>$91I9EJ\VQ"M>LY"/J>ZYQ)9M!'\=KB,U\K:<$JF.FTI%'Y#O6$ M73:FII*VP$S.OUY5T#%48E*54K-Z=KWF&XO?BR-ZL:L^AK]LNXRE7TY(*EK? MK"=\J0^4>W+&-Q#9Y"N9&%KVC;]E61"HZ?3D`X5?OCFH^2T1!ET$G)Z+"")5 M9B/C@P*25$32B;M2_.(7A=\3R>2J*ZZ'YRF=(D;5IV36M7?&6_5=)0[RHXJ2 M/-DH3>:5$V3SK:U;0IR]+2PP`I:$`[#XX,MP2$BL&.MW2A=(0]B1B1EM@E.8 MLWI=^5*:V5_S3TC)O=7@+-M7E/Y3#FE%V?31_HXK<9VN>>)W%7`*8!BDCXXJ MV!.=D-4-%(D7)6K98&1S=92$FC0OPK*54Y0Z&V4I.@8J/#[,.$Z;IPE+6/S- M][)I76W$%>(M7O63R1,Y?#=>M9@N-H>A*V-3>\JYK^D)W`B<=ZOY[D)2N*B: MU5%:G>36!R6LOXRE[9+R^)2!80-AD1&B)JHVEG)[O6=J$.NF!JPK7UKZ:V"#N:M)96"'-;'6:HQS79T+" MS(C"!G/+<*%TK;;>%VFU\F[R.`4P32>T2HCB'G=;3._28V60P_Y%GEB76_K6 M97B)L=V[ZK7JP26B-K.:OWJDE25E,N36).<69T;[SN'-L9.XIE(WE)$P"N>E;ENRBOM0#OB+T=%2EL. M3DBMZ\[VB4\92`W349#+M0,Q)3MMT/%(TYD39ND12VFK:%2N9C2CV&-W43RG,JJ@5)6E=R1OL>*6^ZGK@[&B3D))!)`_&MQ)MML0<"U1+2B/J]W%_*#1 MQ=8]6RR-T>'=1KJ,L>$Z\:2:,%^GH!W_P`36&4EE'LY?(2L6;PJ M+0&)]0RR2$:%9AJA3@RU=L$F?W$,Q#`!5"G&*HC,.BI7[MI7O/C..)-NN8U! M8(1(E>J(N?;0B$`?D#)SFV9A'@N6L="W2)>FUXAQ,*;6F>'M)X6,_OU$?&N8Y17\\/,A3MX]F@&*S" M;-IJV3/A#3)A%OZ=H7R]Q"WBU*JMAP\>,_Y+Y=^5GC55NT9-N^U-ZRTO--1C8(:V?>E%I!ZB[V>:N_?S\KP MXSL96;[Q[HA>:53>]>6=Y']R78,LY.\FE&RZS_(M;U[3.V7ZA6E>A@TQUALJ M"S5Q=K>'M;F'T$"I,XZ'M,[:GMSJPCI6J:42D;B*$8<1 MG#_I`%/(6>A"VB%6/GDL_<00@--TWWS..$E%F^;KVN7IH:47K4%NWG8G0+'H MQW01+T@ERP+D4@)S-Y%8G(+W4CTG"VI'O-D"2UAR642:(RFDW4S?R>01WF[T M;7XWV.2Z)VTJ<1&J?)_0$^M:=A34&AEM2ER:X3[II(< M^KXO+]P@BQY[(.8)+`ADC!"RZ<7;_N6-PFTMQ1*2!'88A+8]#$R"JLF!USL/ M%I<+_M2_!3/V]=I-!O"INL87-I+#(%*^C].71O0"9I4BK)NI;XL'<`8Y@@NH MQ(6=KR_H!U"9K1"[$IKN6%Q:SWX\!."(A6-SHI>JAP6PB\X2`CMUOW1)Y.C%9K-VD9 MET=05;/BAR.3P^X$REK]\$GU'J2#K0$TG4U:SB/\*W=8R592I'NN5S"XZ-FL M3;E',\N'F"'2?HN6#5GU9V[0'-D5EMD+S>4C8V0$/D35UNQ5;4Q:L'8;BTM) M),[/V`;^1(<.=+A],3W<;IN%'NT^W4S(6L+XJ2-U)`9W#NBHF/6@&:H;@RY5D\%U*_^YN7TPMNK<=IDEV>26R:\ MJ'M&-R7AV_+TD791Z4V,"81F"L))H>@EI\_QN/`X?:)#=SOI#Y'19$$A5LCA MDF_0DU(V(8GJN;S8PY_:WHF]/U):;9Q#VMOF<3,LLU;=.WK+HE\7XV!34VA, MZLM$67S"5A8TLTD:`XT).S%EJ08 M($6ZK;01-?5*RK*>JP5QM+@>=1BP93(XC,;]E(FFT393N^ MY&TR0[Q.W,E)`0/I6-E]9#;0&9B&I>[G\5=P9YQ?:(JO)6(?HV'&N:0K`W?2 M==$8_$:XIZ3VY#9EKJ4F]EQ]7[LT.BK3&VW>=5]ILIRX:VF#?)+S'TBW:N-` M$[[0]<1^BOC?7CKI/IN^G2[JV9CU-'B\_JRO676:C2/N>O5^ M?IJPLSI>=F2)=V5B#^EXF1,P:W8#+'[[39P=E[A*5'&PR3X`M%Y*XT: MCVPJTVQ_3/W=UCF/3>1I8([,)1V[UHRPZZT[`,MKC=0"1#Y<;%0\ MJI)G#Y-(1]$_O9K(/0(0>$"#XQ?M"\>@[YZ"F,#]M? MR'LEG4R<#(E$YS^LEL8:_LET0E[(''28Y7.[4)6GYF)*=J+LV.RZN9DZ`]#" MKML"IOC\7L:42^:6#((DJ2@$0O(VGSP;7Z.OQM5M9@AL.^0-$T84I8;U',K%LCHJ1" M`%GCZYN=U/BL4A-93-A?$KCSNQM88+E"/,EA5ISR05/5F1#F5(/$+%"/!+3_ M`$[Q$*5:-HQS?,W:+-?'/!>B`LTEDQZ%C\^9R,IR'RK6[J16%^K6.EY/5O1/ MR%K$A!,D0E,W(E#8."SFL"9$@1F!4U"C]53A;2J.V M\[+LBK<7Y\ZM&5)-_1VO1T*DE7\SA)!1T1A5EV!!XZZO[;JWJZ6F/N4,BTG$ MQN=%'T$7JO4X`F8TY'344-"F1@6_2_1^,IOTMYWG[!M3M#=[7B$NZWZ\&%LJ ML.Q3$G,2"O@/3:G5L7C_`,@R!">2.02DG1[!2;E'Z/.'M'L9?,&]0A2A*M4` MH^ODJ\1C.HD@SU97P0&S/WQXI2ITQ>(^G"XS/CF<_P!-CU.81WPO64B&4-+> MFW-K3,1VLI>PHW+A#J+`!5CB5JW$U M\%+-K0;&_98@M(:ZC$T&,3YB1$"ILW*QX.0#6\SDGRWFC5BTS9F#KQG;=O^5&'86J2]$:+0F2; M'!$T8^@7:"SP.0C7KB4:!`)$66?BJAS#MGC93\],,S78_=*W+!XU%VE7')(UJ"AUF@S!YA,Y"Z]U&EAJ:;4>T1^W$M1K MML[??HR*35VBHWU%2EM7MLL\6*[1;Y`KKLI.!QNJX[SQ.RMA=7(<\PN\HU+Y MX?YLL"/Z(?SP-O+]96'8ADOQW):.ITYT@3M*25-,HU*I&5E7."];!J;AEW MO[==_KX:C)Y,`)12Q(9$]*N>Q]D4_B,3?!WDEUB`KV&G#%5R:B_A;8K(8R^"%U!'/6^9^7[D`TA\EBQT7+)A>'M-`HU$*E]M"R M8/6YV?/.AN=3&T@B`)K6ELT#.(I'K7D;E^M*2#)I/XI"Q8K8_#2P1:,([FH\ MX=C3IO"G,2XAVRGCU?!2MWKW00[1=3)Y3,?)68%&A?2R!..ZM&R+SR1$&`-R)I?3P:Q,3TOS!&%D M_(W%PC9BR@T&E:%B2C)!HL"I_A]92?E/Q'S@/673=^@YA-.?*CLLM>R9#3MRP,7`3&>KDFJFLY#; M\^B\6.[-O=)`5`U_$96:U?CD%8L76C9D0"D1,RR4'X)I;6W:;WM[M(D"E.E* MYOAX?%1)K-@)Z/1V$39S'+"A$@@9]W`+,TD&U>3T<+D#1JY<1F7J1*5,V"N^ MJ)1@4C9H.?%ARK!5EX#4?.,G*6FOES/SF+-I-)O]VYUJ9YBO;H=^(KZ86(7D MU)ITO#6TM69VY''475W,B'?KKP.2]@Y165M226G@F+&V*Q$@"&G3Q.4KQ><1 M\\B]T[^02F(4PFZK<7/I(XB:5I`@I=A"),SKZP+:J"`R>PII3<2L!R+4$.9H M+$0R5-W'NZ6PG[M&9/'6+\E*8V8`-1E)VZQW2;B8^32-M"(0_?R67Z&AR_P"22O6S*G#=>0"VIC'K9LR`QT`24J6PF>M@5U8\ M5LHQ%;"I[?[-XVF34T5@K%%J@\7%*L(T=934^W$1`@*/NQ52WNM]UMS?K]E+ ML;BZ^2#FMJP:$_=K4<,$HBC.YB[:5%.ET:LBB5G3FFI&4M'?03](CM"K+KB8 M1B6C7/YY8?N%(%VC`@`'DBK(32^GGG?YL:_>WR,U76=<7C)HD-DA\]7$+Z-= M5\3D40E0"J+8M#F>*S,_9%8Q:PMAWZ`B:C+J!RQH6U;^)IOTHA-EXLY/:P^0 M[#152VZ4]VNZ3Z>,^*)(,][\WQDI)D91()1&HI&2%P`=K2,P.6-JMD$LY_"R MR071#(G,4Q:S60RJOA4`GZY(6P1W]++P*<#XNL>)1*0-!X:7[;WAQ#\91[89 MV]3$OGP^KWC"SJ_GA"1A8GY'K.K630==H?DU=6!;,:8O'A9KJ,T^_0"L)F<8 M.4GJS31R'<1M\NSE2+@&@(Z6K^-FGT]SU27J<0I"^5+'KD;^Y(5U!:]>0X$3 M-($03E.%6%#IA+Q$Q9#UT=77N[YC'1SL:U?I-_%QQ71PKJEO^%/`2ST3?D1[ M&ODCYKE4<828?Y:S5I)XC7/-[+DL7".O:.L:U5:4ALA(F[):Z%B1&/-0)/WT7#Q\=B"#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(^M MFNAMOU99-3F3,EC@BSH%+Z^*2&&%?L4O!#IE'R$>>F(L:_(=>"9$-;D5'@8C MLU=:,R*+==1LXT3V1W!.&GQZ&I0>U80NKJXB`P>+)1GHR4%C&NNRY9W)@@-]J72'^D!3L:=3<];;O M=/=OA>IY%/C7@K-B4"1.Z;DAD9F3Z*D+0CX?RMGC>Q7,$NB5W=$E7[\[7Y4K M'E&IN8$HL;4BCT/O(H2R"BGWNA$?L7<@JHV5N_$<]":.C^/HETD?'GI!.9Q$ MORJ@M:D3@V*>17=E)83;!FN9*1\>[R&-G'P\N`DE6QO7KU(QNKXY:ANFQ#UM%#A1C8!BC MR,)M6OIG&'0LJ&JR&25-^[8;R,7+Q"+D>;2CSDK&R0JJ:MMX\M[/JR=E>7H) MM7_.U;MRLC:@N:I;7,PAJZ.P)$@;)5K'BD=%IR?5H":BMT"J)9T^,I@!8!/9 M_P"Z^C$QC3SQIX).>O[R0Q,.!HT4EBDPKBY;5I5\VZ)UZDC0R$,JR-1R&6\7 MIBT:.L6(]5`> MX$#$ZF]FRF^B6A*SYF?TB4,(/_&T/8P,8,C(FHXO7H"'C0T9'MV8UP'':R39 MUZJ7*2(H8W_7^"3CI_G>2"27QUBIHB/;7!T?>MQIQ&OB]8UF[F#6GAIR%1B0 M'X&<..WL@AM61DK.Y033K>+AG!N9N"J&[!!Z_P!Q>\G(.9!N+JX27GU7/7Y@ MW^P^%*VLC69^$YM9P)2;WA8%\OG\2.B@)H1*[$X]DW%Y1K&C*(-5\&:"J]E+ MV61]\BIN;&SYH/)^DUQ*&X54%4UQB/*I5>Z\B#HE\4-+Q=P1>)SB6)+E?V#Z MY'Q.%4E6,6:[UW7'2%8BE!<4K:KXP(;+%0W34Q+2)X]3)$B4C$`7:;YH,2=A MW`:G\GE/=]/]30&RXS"HW<<-@KFN$-;!7AE<1>HMI8. ME1>OBLTK2:R^MH7%HA,)!6\@CBBS(&/-1A"*S5-25JOGSR&KHLM^=^S4\ID- M6G\5L%/%[,LF'3:0JV,76Z&F$*8G@E7IZN)G>-"VU27[U%#$&Y<4##,&(*IJT6LM]FGB8FW%[\EO.;^;'M-.2$VF]F M3*V[6DM9U-5QF42Y*'M$Q$+J-.6O8S%@C.%1.'C5TT9%84X.%Y(2'N#TC?F= M/UCAN+%A!`L1N>BS"Y>?9%8&WQ9P]]5D:I6=='7Y8-8UW5MJU;4\3+L:-!-J MZ:VU3 M9C/*3\.Y*+[X^J_+/WHPK9MI/:FVGUMVV%IGQ6#MHO';4O"+6#&+!EK&0H0O M2=/6SI:UK&F`>,F9,2`B)Q+GQGQJZ8BHL'CPD]%M>^T1O&QHD5^+NH(W8,9L M5Y,STH-CB-/R*7.I%75"/3TZEM'0R(P"%&U9OM4_[ZA3-[&*^@;.61JO9'&` M!I>*MW;-D'5D$W_=0NIQ'?=X;F+MK=]>I(<"X/"0K>DV#R];NF$/YN*P=2CH M%("$*;Q>&1RO8G-(5&P#]N`A@=Y,'R4;F*85U,Y0[(S!<7%8XAH61=.9>^E8 M:NBO,YO/C\]OYT^/FJM(U>\7\E]@_HN@(!/:\E*_KN.?JA`FPK\Z`Z%*O(_M M^W/RDB+.5]$RP./W(I$6VD>#1U)RVB2^R-5GGQK5S8T>E]? MR2V;<5J%'6-EU?-V5JD7"?3MO0&\A-M2(B7E?0UEM*&I6# M2]:4>N\(2>P0YFIJ1K:*.I681+2R,@(/&XVQT+-9#Z0D\R'-9$?#Q\74DU&T M[6E[7;LK9;^YU7GE%PZ=-:8'[[/HV+HNR(G9,,%1O4>S'^/(9')#%PH!VW<, M76ND=2&2)QIZU'_H76FS1EJ@[11T525&4XGJFO,K$O\`'76'D0H>-B;`LL&7 MYLIBLZ@J69LEX@X/!5*EEM>S.(SE^U)1-Z`+R'X1 MOL]:NV(NIRW:[;?C/[DVE/43@:G&FT??GQW\.$7"P9&`,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`*Q]B]2PWC#G:?=%SP&=DD?@ZD4 M'^`H\L%8OB9R22<5]^E$B+,`\>#>/BSM17QKHU<# M5-.II+?[*2%"?R,U1&A7&J4TA%CQ6Q.U)@"B4&JAPVBQF5PQL5>IBGLZG1"/ M28K%FMQF0L0!D2;;=%VW>*B3\C M6MWQ?HGTS$['WC/PSPZ'M&KH!T+8"4QK-]2B'+DI?0^%O$J%AE!VW:%OP>'/ M06B#9G:2+PK;\OCDJ,2%<81+15,"S8^AR0Q>N:H M'SWSG7/-0[U:S9D*(NI<_5?KG3D@/#DV:8;]8=DKT@>69M6*0] MBX=>(,D$D&Z/FHRW+;Y-LI%HU'P9V/8-F[)@.LBZAX]BT13;,V(]A5R^9,O$]GCMJTU6<-F:6SEPDAXJ[>K:MV;5/ MU7?3S=P[7WT0;(:_55=;;5)+7??;S7T#T^>^>_S\]\]\^OOGU\]^O\]??==O M/Y?W^>^>^>^?W>^>^>_S\P#_`'`&`,`8`P!@#`&`,`8`P!@$5TY_PD7_`.:E MZ_\`6ZPL%>?!>R)4P08`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`@6_ M^H*`Y;C#66WW:<7KD:4=>#8XP*.5WLKF9C;9/5,!`H.%;DIE/9$OLJGJA'X< M!-F5OQ^>ILMM?K[X*DWA2?F;[_/]K=E7I7$TY*XHZ=YK``9?SQY/+OLF0-Z6 MEW0L<6M3?>JHR&K9]#[%'P290&0IGI5%[>G;5O+Z:`F'FL_CT;#2L='CKY)T MITTIZFFX<)7A\S:9M93-S],'+0Z!B.?*K&5G6LSI^&,(SHU&UK8P,R`L")/4 M7KS20#ILV/N'Q4G*U)'X6>R"5N"IY.;E73J9M)+)F1YN?)#F\N7/4G[!!@#` M&`,`8`P!@'\**)I)[JJ[Z)I)Z;****;>:)IIZ>>[;[[[[>^:Z:::^>[;;;>^ M>:^>>^^^^>>8!_NNVN^NN^FVN^F^OFVNVOOFVNVNWGUUVUV\^OFVNWGOGOGO MGOOGOGOU\P#^L`8!%=.?\)%_^:EZ_P#6ZPL%>?!>R)4P08`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`*_\`0?4W/_+$:8RB][.C\#;&G?@R*@U_7AF;SLUM M[IJE'J[KZ/-2TWL"1+[JI:I`H<`-%-OS/-_6NJ7FRFHJ3JPI^W=X7B4Y_B-\ M@777]334$UX`HY]]/II:0NM1<*A#9'1)-K&T?$_,$=3=L+A61 MU#7(U1^9?=QZ^W4Y"1 MN,6(6@OQDEQ7,'3$`ORN[$IM0(QB<5ZA)5+(.?P?54O$R5J.GG;K MCY2RQSVK>G;/H@OT11-E]ES62@"[XYP/S MA'[3T.AK?'5H/;NV5JI&2?!>R)?P08`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P"%+WZ-HWF.%[V#?5G16LHMLZT'#W4A?>^$I$86^GC6/0^., MDWDDFDG?;;:Z#XQ$Q)D^0WV\T9#E]OY8*DW9*2D'EK]X]@_U//\``U.%J'?? MT?+]Z-B#:1=,R\;O_P#IU3

?A_*^N"JEU84^WB\(_P"9Q\\EXOK@^3^_+""1RXJO#G0=-?:XE;47-UC. M46+"F8&.;%B<%*.=3,>:R%-KJ<#M#K08;W$$&3@J)&/%E62(]?X:6A2D\WL] MWOZ'[:W1-M=?-E%=MM_?-=?/-= M?/=O?IKYYYY_+S!Y_P`7\]7A[([TX.8P!@#`&`,`8`P!@#`&`,`BNG/^$B__ M`#4O7_K=86"O/@O9$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`:58ED5]44-/6 M+:E(ENHHMJA$ZBBT.% M^M=]42GW9?79VH#J;MA<+'CSW-![1R_?NF[%BR;K.WCUXNDV:-&K=/ M99PYNV^^VNNOOO@R*"B3'G)B+>T_$B^OOFOC:QNF940`T/$OR=_S-7PQE-)),FOY"VJ40=+: MZH[C6EY?TKKE]EE^QA?X(_(3TC_7]!]%1[C^N7W]-2E.*OQ2&U7+!7^NT'3+ MK6SHXD\8/$_ZML_]IJH:_?)^ZKZBYTKKLF\V":5A3UJ^R3]V^Q9'G[B;EWF% MT0-T_48`1.COFWLIMJ2+E;`NJ9K*Z:Z.%YE1J.D7&[L@`"OG2GFGBCEX*8N7"GB>FJ>GF MZRZ&ZF_FFFNNFGXMO?PZ:ZZ^?3SSSS!#(,V+(VA MGGU(I#6F+U?2NWU/LONX7<]U<_'X/D4S!7AV_8:_8U[`GFIF),I0"2`6R\V:(O-9@,U4]'HAJA0K+?E]W]E"Z M%S[Q%Y_1;]4=?M931%'> MMM_Z:)F`U6N-TZ(N5LNEIOLQ42B580XE^)!1O8NC=7Q;!K2E^9WX5WY_E7FW MT/2R^-YC;CIM(^^;RG_:AC1PB_3JPTGY5/(X%V@IJLW3$\T0@C]AF23/;\Q) M)Y>LCN(HIIM^9^J0W_EJ&J/RK3US5Y[>"1T:C,7C4+`BHK#HZ#B<7!-$QX2- MQD2P`@0[!'Z_E,A0<6W:CQ[1+Z^_EMFC=%'3Z^_AT\^N#)G,`8`P!@#`&`,` M8`P!@#`&`5)[IZ#G7+'*]K7Q6]8N;;EL#8@'#.)HHR%RR9CS$K!1\]-Y`SB` M:0RU]$ZW!%2,_EC&,!'YMW'8V209^,O=]R3(6E)M)N%\]\(I:P^2:UO8CPW9 MBE74/+*FZDF-;U=+[%KN^)`>"BK"L*R3%VBYJ`]#W7,K=G5+ECIP%T9RU5G3!H:QK%C.HO]TD84S(6CH7$)`-,O MHM)!'DH=MPS8F,8R@608"32[$5N69_HG>XYBNZ]9I##4-HD*C"#`M!'A,4^9 MDQK^S+O=L"`]RB\8O6B]UV"H@Z:.VVZB#ENLGMJHDLBINFIIMYMIM[K[Y[@/ M[+V1,&"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`JQTKV+2_+B,<%S=\?EEHSY1=I5-!U: M!-0J.-FXN+"?=T_IXQB-=P4`TU(2$TXV4\\'Q2%@B9I^LI[XS M&N%E/?Q#*3;M=E3M;U[HZR_J.7JA;\BTV^_H:=)=>Q-^\MD^/5^FOI6HN1F1 M,.8&:[I_]X%'^@I7!M_=5$7"U7%VWU34%A++E\+'C5^T]T2?4?QVT;!9L,N: MV2,VZSZ+&^^KLKWZ9,-+`D46=J;:++:U/"D1PJJJ0&ZN?%-VC.IX-%'6J"GY M)`D4W\V<;@ZGA?2N%]]WXE]L&1@#`&`,`8`P!@#`&`,`8`P!@#`(1Z+H.%=- MT[,*6GSN3C(_+F[+W4W"I,8A\MCQ@.2:&@$@C\A!.V1!D1#F1[)]JCLJH.)H MI+"3+(B'?/V#D5-IRMO$JR'^+KE8.PJL2FVM9R$K$@#D#Z-.;EL=6)VS,(Y< M)?H4--;IB^\@V"V)*&5YGS5GZDBS779R=?ZCR&KV-#Q0)B+K=\>2M*B%Q:W3 M8QXWXHN/@@B6BP@*QQ#D^.#XM%A2KY\5=(#1Z?X?%B!8HX=E"Y5^OLL0+%R3IR1*DW3L@^<+.G*J MFPRW+E[GFIS_`(2+_P#-2]?^MUA8*\^"]D2I@@P!@#`&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#0K2 M>S<;7$V)UN]@H^=C(V5)1=W9VQ1*O$RP]JH\0UF3L([9E1D>6\1V0)F6*BRX M5NIN6\8%-6>PUV'?!P`YA^37NCY,);:-<<=P2D:=AU9V-)X?C?;S9R+>#HZ::4FVW,- M);\R]N-VG)TZ@M,:?UC$,0EY3 M1@W%A=5D=6\+J"NA@.)#MDF["*P_]?OMNX&9=4)+M2L+YR[\LC7_`'B.QNPO M^X\A.DUVWKN&$*6=M&D4J*-;;;J:(Q&H8Q!XZFV_`BLP<[:?G;`ZF^$N$H7\XR MY9=W!D8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"*Z<_X2+_\U+U_ZW6% M@KSX+V1*F"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@%=^D>I:>IO9(53C5=5[$Q#V M7VI;A='$AFLK(J;IZZ,AC;UH-0WV*'GX@*W>$FXJ3>//9=WL M?G^^7)7KF5?'CT5U[U$)$5U6$":5HO6/QY-I5*5`$G8S&XZ\@JQWM.S*DF4& ME$]D6@>5/B@JFJOG(.L(>9:AU9,;L]^R7\2'2A+6J5F\U+L_RRH\6IX@X3?% MI\J?6%T]WU'4M`=U6A?2N%OW>_MT.@F#(P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8!IU@6%!*HASPJ8*+MF+-' M995)NEZLMKZNY61;(^*+K))[A$V5V1VSZAYI(+U6T9]"4BX>WFR2)4JPTM2# M^$+<8+[^)I.JT8;'-7DX1V5]_)_'&D"7GB_GJ.WT5U]T\%AWL[9MCOP>%7K; ME1%O9#M;IKGQ)K3:_C6WG*ES5QHA53G8RK'-6]D*[23Q.#K[2%!<#JC)]A:G MIE%47YKZ^3W0\#2[6=\6=^W)-X0V%DP83(XV7%R"/'AK$R"/!"#0J&-!R;9) MZ-*B2C!5PQ(C2#-9%VQ?,UUFKMLJDN@JHDIKOZ(1_3G_``D7_P":EZ_];K"P M5Y\%[(E3!!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P!@#`&`,`8!S]Z`[3+"[$>\O11ENAXH3`5>!T(6Q8*+?5&/@AXIUM)V0TE:79>KZ); M^RW*S[MJ.X0G0JT>@YG-^X/DRND,[$PP/$XLTD-Q&PNV^^[V`\UTVT?^QSG7 MGP*X_.VD,I+EP,?5\27,6Q9LA->MO?!;U644TKR_[/=\>B1C[F^/;H#Y-:TD MT<^0FXYA056R[42XC'(_)4N`IL(=J,.C)$.)WC(+#6J&X$;%0U M0Q1ZEZ2CXN32%F'FK(%4J6M*E\U+?HD[+U]B)^,?]G&XHX;Z7K'J>J;4ZBD4 M_JAQ)W,>#6#,:I*0][O*X3)((0\,L8[3,6,KZ(B)0_@ MEO\`(T-D,)A+^&SOH&X(&3YB@-T2+6L>G97;7,M13IP.5B2+".U*U>`KAO=6 MJ(ZMK9-KOY&`A?K!@8EAF4SP\;&M5/U0WT3EJ],-^.%+LLWQJ@+X_NQXFU)]8TKJ2P'8>"C(I%B41FP63C8Q M;2%:IF)V);^NHT"(#UI,-')!X67;69=Z*Q,AHP3?/U$[KL'7=V[3%,1@W1P MOMYZHKJP'LFGF^WOB#5%/\*>HC^R]D3!@@P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`/&0(,!#!\5*OF8P M6,9N2!(D0`.YR,\>R]W1''X;8DTM3Y`W[5HT,3P:)]63D\=XQ&R)#86\9-TV[L>8 MZBE+1:!1S=-^XK,7-RC!,X,&X5.;U;4_^V__`%SS&\64E)7\MAJG.7Q!0D!6 ME!CS9?\`B;\B%BB'TRBLDEKIULWF4CI,?)7/[E["N@J12<[F[JFIC:H&)-EY M^=)+"]01C*0-;UN]HIQ"Z_I4824]CHSS/QU3G+C>1%(>WD$TM>P%4'MM=`VD M94F]XVV50\U\2=3:=OTDW7HME[KYJ"AD?;@H)%F_T:QB,"&_N^FXRZF^VR5D MNR^^7NRU6"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(KIS M_A(O_P`U+U_ZW6%@KSX+V1*F"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`0K?W0]/\`,-;HNR<@E4E*;^H@X9!XL)0>R&:S:1.O/T@")QD:3.%G'XM6C+?1-91,5) MMPKLXW]"SQY<`F,V=\C;274_S9+#J+;F[XNH0@M+^E>NI0WV2?1W3H:*0YVY M)S-ZXW_1E4N9XNZ]K>&?G,B%_P`R+ICW@P0-I;4WJ6:\)+%I]W?@LE'>4+G[ M+T!GNYQ(VI>;@V@W:M_CEK@TV6B"@H1XC['G/6\UC7K4=:A%CJW:JM:,AN[: MC(S^C8LS2EG.$-GB`DJG\MW^K_U6W?/;!U9%"A8(8."!!K`,&$,6@P2(%,VX M\8+&L$$VK$>.8-$T6K)BS;))-VC1LDDW;H)IHHIZ)Z:Z^#![\`8`P!@#`&`, M`8`P!@#`&`,`J/UEUQ'>4A<%(EH=()XK*#!HC(Q\:\SB; MSS;9U#ZIC_HU4LR8Z[$BAF1QH&R_+6+>.$!4I^9>R\2VJ2J:R::R*FBR*VFB MJ2J6^JB:J:FOF^BB>^GONN^F^OOFVF^OONNVOOGOGOOGOGN"']X`P!@#`&`, M`8`P!@#`&`,`BNG/^$B__-2]?^MUA8*\^"]D2I@@P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"D72_:@&FI2)H MNI865Z-ZZF@OTI".>(.0:LW8H(HIXVUL>ZIDY3<`Z5J%BZW3T=S.5Z^O3*OX MQ<'C\M.>>C-1I4S=N%SZPEN_CROVS`=MKX@ZDS^4G$MC2HPW-L);+[\OJ74P08`P!@#`& M`,`8!'E@6[4]3L?"EIV?7E:#/4]E?"-@36-PUCZEI]?QJ>.Y$3&M_4]/I[^+ M?\S\.OT]^OOF!#>%)',[ZNH6`4X%OYW-U9K4LF["PYC#ZPO>#1*.[)"W[-OVG& M>>.OH6%]#/S&EEW3SK,Z3@*WZ)1KHB,0VLWR-3)4H4U<[+#$M(=ZV51:N=G# MMMMXCJL*Z8WI[)S[6]33)_=?R!:364QBH>%ZS+1<6;?C(Y9UP=A!X`(DHMNO MNDRDR$/KZF[CE3)B_2\UO('S&(I M0&P..7HUPTD&AYU:=I2UWL-:M7X](:N7T9.M"F[ESILX:-?=`;IV375N?LD1 M_-^%)!84RE4ID'=W>PX5))"8-,:^@5N5[6,,B`XF_CE8RB-='EB]C\H]5])PRE MJ\K:G.:9H$LZI9.B;A?E;$$[AEMEDK(Z5K68SF5VC(YRZA=C@;)C9\!(]::K M^>;IOCWK`HQ%V_-2INU#YMBEJVTU8RB6LLV0E)==W(T"A%=?79[XEH,O+W[ M8ZQBTX+;8(,`8`P!@#`&`,`I%\B]L7527'MM6+SPXB;:W@Z<2;1926NXJAKX MV+S:.BI5M%&$W/QB)R2QT8<\D#FM8B=.-&,IG"(('N@5V>Z!R`U2DZDGC^+> M$YZ'.>&=Q=36"PX84J>Y:VM:96R9$Q:P:7=VF[FP M'P[G2&T'"@ZH0>=8^'!LYOMFH&`#WX.51N*LQ=*^J5"6\VEJ:4K7G_QOU(`K MOY2^RIZK5\.6-U2*.]=;\ERJN)@TK!ZNWYD`=%=)=$U#(81(@3F;;-K*-@HO M20E.)F#;Z-*N)V;.^%AK\8U'BD1IT)7O],IWM5"3MQ=^47F6=J.(.BY/T%QA M270ECBFZ4OF,-VI-M&O4B,$>/T4G:"3RS+OLG&OGOGBK9T@BX1W\]T53TWU]U\!Y\%[(E_!!@#`&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!YWCQH/:.G[]TW8L& M+==X]>O%TFS1FT;);+.73IRMMHBW;MT=-U5UU=]$DDM-E%-M==???`.)W1WR M3KV!%9*YYELJ*4IS7'RV\6L;Y&[#"[2&%.CNSE8=O6_$-9J(+$>J;G(OD'0P M3(1`TM5H@FV42$I6<:\\C:8Z*F/S)M[4+/>K]*]>RN:%S3Q59EQQ4N'2#6SQ MKR58!3R26;M*Y2^6^27O4LNG[XZF74]R).%)%1L-D2"FS?\`AO%225G>@G+V M.[$:A`*ZPW41U1Q4UB/RT]E$/OC>^3MQ5]5UO2<#C=75'!XS7->0\>F+C4/B M`AH$!"&>GNV^VK9BR333V7.%UU!B9N[LW[`&`, M`8!XR)!@('OBI5XU'#!C-R0(D'RZ;5DP8,D=W+QX[-)6 M1A(2V&+(C)-H7>$;"PER?M$(;_:0\"A-X**2%HD'R>Y$:=+2E3&&WSTZ<%G+ MBZ#ZN"V(V2+CB#)F\=(ZMGSD$J8EU1T2;?V7J2&ZC/4MB<^-`1ZQH'S?T:55T4- MS.F1"=VPR)MT)4LX\91-O<47BVD@=D(8FU'."LDB#5N.D+IX0;!'S%HW:NA+ M)XE=;3Y8\S1Z6X_D%83T?9TZ["[`Z#E;)D3;;BK1L:)A*M55+LU&;IQ_!VH( M!6->K;-=5=E@VQ8,7[`&`,`8`P!@#`&`,`8`P!@#`&`,`CFW*BK2^:XEE1W#" MH_8=;S@;Z*D\1DX]`F))MM5T7C539!?3;\A^-(-FA4.2;>HD`Y=DQ*C7+4@S M;.$A4VG*<,KQY\=G"OW6L#RG)M$+':7$1T%51M>N8XJ6@8R*2!_+0#>./]V7 MKD=LPEA4K*M5T5/%UY(5)G7*BQ0@[=+!JJNIR4.:=24,>"&F4Y_P`)%_\`FI>O_6ZPL%>? M!>R)4P08`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`*P]*]?4GRL,`_Q&,EC$\G+I875=)UT%=SN[[@/I:>[?8JUK4)^: M=/K:[?@U(F5DV$4CB:J;V4R`&._$\U%5+AI6WZ-Z1C(E, M1"9(^BX^(4WSP#_3)--81RG1P]5W%J=C;)@@V$[R37ZJJJN^J:222>ONZBBB MF_OFNB>FOGNV^^WOFNNOGOOOOGGGON`41??)-R@]L=G454R^1]*6.I(A<>.1 M_F"#2B]AL#V(/D&3LK94\@@\E6M>#`'B_P"K.ZRZ9"2K9LDMJU%O7FGC38:T MN):A=;>2=WX&Z=`1WN&92\7&N<[*Y\I&KG$=;+2BTIO`IA<5R-Y-N2)ZO!4) MKC4]`ZU'C4A*(99M*Y7*94HH_?$VJL#\0&M7A(1:=Y;X4)>+N_"%WXBFY.0[ M?FO%UD\XDKI(].SBS9%&7DRDG2"T5@`B50I6CJ\F!2+&9#X6CURU5!M0_JJ;<948WG4^7YG4G!D8`P!@#`&`,`8`P!@#`&`,`8`P!@#`& M`,`8`P!@#`&`173G_"1?_FI>O_6ZPL%>?!>R)4P08`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#EQTA\P?$?*5UG:$NBS1$3 MG<66@SJ1I.Y%#G+8;&)F%*&W,@5:"9(4D+1[%&K(9N9@YP$$GY5E*8N,-BWHTJ*JE*4^902>_."[Z$A$"WXLB$KKP5<&A9I"[/M"N4[)O">N1!K(IH.% MTW5ZJ>OY:',''C>&P,0.<:C2-@&E$72"P55K"AQBT4KK2LSUJEG=&K*GK.D( M)'JPI^!Q6M:]BK/5C'X?#`K$"!&(?7W=39%BP112W=.EO=W3]\OXJ^(O55GK M]PY=KK+;CG,W=V2#@#`*H7]W#RQS,18QNV[?`#[",ZZ_MNGXHV+V/=TL553] M4;HQ6F:\'R>RSWZG^CHFY81A5@GLHGLY=H);?F>"JEO"LLO"7=NQ][>,]33R MOJY(\FI5-`"D[:,C$KDG3L9LC8Y6<:,!&I%EXTI:.^Q@H?L%JX>>LRL3E\\K M]K'GK-9$DN0735&^`HWGPCWO[,^O/M!616+>;$+LZ;L[J*66(@);'O)S'J]A MM91MH)3+H_:JRJN#1H:PB8DH@851/??3TU/']&8S[U(7_K!#W4&T\*//UDGJ M%P:%5O&QD-KR'Q:!Q`(AXV#12&1\3%XV);>?V-Q@,&T8C&"/G]R35JEIY_\` MJX(;3@#`&`,`8`P!@#`&`,`8`P!@'+[I/Y'RU'W[(^?X'S':-]R6'0*$6%+' M->M)D;5"`IP[E+9@]=B(+65BO&S%#]K.M$E"*@XI('V[@=$PQ]P+)?IQI4RI MF)M?I'+7/[EO^5^@@G4]"0"^8Z&<`!$\1D.S<2Y?HE?6RL:EIZ'OMVY-!!IH M0'NW\?=/!;S9FQ63W31AY\<6+R\6%$-SK1`'J^5)D1K9V+I=[8R]MM\;FF:?)3R M$L#G\E:S.QGH.NYVTJ]^39\Z='+LIE8Y"P2=5L8-3;K6I_T]\29W/PQ..I"Z M65GB^JS)=\KXF*T]?X&EVZWRK+-[V\8+95;:$"NNNH7;5721G+Z\L*/#95$) M(Q2>-D"P0JAJX:./69%LR)CW.NNWJ+T649,BHMZDX'DV31\V<-TAG%F8BG/^ M$B__`#4O7_K=86"O/@O9$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`0E>725!O^Z'Z>A^WC_9XN4@G/7QM4A(99S_\`PNAY_Q7-;O*41# ME87W.[.#F1C;-U4_0L2=SR[;1K^I(6R_%XXE%C2X%#@GBNNGN_C9(@>?,6[E MZIYY]&[%MNJ\Z)-T%5=]--@2;PI[$3L^CG-R\\D+LXWBX^]2)%UL-KP-/ MR$RH&,2Y=M)6H`L:4DLQKDD=;Q,8RW(R)B>%0HVREPX9JG%EW^I-B\]%B'#M MS$/[_D*_]&-QQ-JSYIYUK!J&J1DY(-_TS9_*K6LS]RW! M8901I[LY8N@FM0@E'_NJSR).&^GC3!6Z<)/NW?R4+W+!02AZ3J^43F<5U4M< MPB;6<>)2BQIE&(F MQZC*'L@@U4R7<219)PIJ&U&B452+SQ_^1N@STV<;Z^)_TL`H!87S`?'?!*W" MV0-Z2@]L:RMPJUA5>4D_0M"Y)NLWD#J,.O8O4T<66G#]HU+L'R3@FJ(;"TV[ M19[^M]9_EK;C2HJG$1ENR7=O!X]>[NB[4:M=^6OCDZ0EK9[HW]UF_416'<<0 M!GJ]_+\0=J"IV[E-Z$FK77?=R\^UT@MJH@CYXP<.MG"/OH:4LU+_`*_5_'J: MB_IWY>[@GX1G974G-O,M%N0[G>6C^0H28EEYZ$U?U^B(,-8G1\)F$-49Z:^# MME9DRKN*%=?'#U)E&6J[%L2?!-*6&WU<+R33]3F:1X@LGBSOFS^@)VRE7:\< MEXJKIQSE;?2,4Z:Z.F59V#!_)$.,1)KK0%Y)!$ M-7?CW2`ZWO>MC7*+@?ZCQ5QKLYB8F$E/C$EZL&1@#`&`,`8`P!@%0.]*$E73G)MOTC"F=8E))-0PU,<'N&.OI'` M3*@8^*/^BR28LB**@"CG[7_^%9L*=;$8)*]`LO:,WZH7QDX%I<-.]N,_.F^" MK%3?'[9L6K[X]64\LL+,;&Y+OB4VO.96;7D\F.$J]-5UT]$83248G$H&^C(^%&M2LG+LTYB;I67BIOZ-LZM\C7%E6\@"A_P!PF""(='4MX^U"Z-FSU93; M=QKN,-RV_D$H48Q1&01X/;;O%$&5F7>U14($'Y9]NFC==@IZ;.R95R\)/W'N MNOGJKM^[^_3^?O\O//Y^^^_P!V M`0!/.L.6:KV5TL_I6@*XW0V]U7TGER5U$-D=M??IMJKK(9&.]3VU]_E[YOYY M[Y[_`"]P5)O";[)LK>5^6WXPP[CUJZ[VY4<+:_7_`/(UTPB0I>_3^WS5<`6) M(;^_^KS17;WW^[ZX+IJ_35Y,^3#Y<_C"(J_D)=X\O-%/?I]/#%N10!K[Y[_9 MMXH^?S\V^F!HJ_35Y/]C18G\CCF]+,L^'\HI<4W/%(!-A M$&"2LYWFUBARQGK^M:_L!Z=A\0@7/-T,R$58NYVI#4"[27O5'LCBLD:JLF"S M'=MJ#IA*=2W_`"XNUNT7QY^MEM?="TE>C(*O&F=T5%6ULM(ZZ>IDG(!M8T-" MS!`*Y(HMVB3]<4D8T8K/4FK9-THALOHW1U4\3U$:AM<."7<$&`,`8`P!@#`& M`,`8`P!@#`&`,`>^^>>>^^^_3SS^?OOO\O////[???<`IG;?R(>#GG>?SHUA7CM(%7]"V&]D#[?5,,MTC((]R_E?UM2O&I%<=KC^9OM7Z MMJZB,OI*OBGU;_=8;#4.1X?L.=>_B:OU+QZNBMG]629KOYM^>H[K;AVG73A@ MDEX-E+!=]JZ2?/G^"Q13U\=3\%2U3YU/L3'2'P>?ER?VS.F>@3YF=$]-=SZ= M#.IK')N8_'^/1X,E?8MNRZTNQY&,(I*+^%&,`L^C8L_W<;Z)PI@R219:`Z^% MYI?^*BG-\-]3L50O+W//+\>=1CG^GH)58PDM^K.+Q8&W;GI20_%OML6F4J<^ M.91-#2FV^^RIJ5F#!9;W;WU5YO@PVWEM]_L47^27Y%Q'%1NJX^QGM-Q@UN.- MW?9(.T3;-F53HT:R!KMO`)?J0".4M-% M41::9YXMR^>BW+00Y8\+8&R<)).M&P]U.6$1)#6FKKQZQ:F$M4TUQ&FG#]TX\GGH[D-PNOOD@ ML68Q67W??5&\\P4%(@IY_1?,L!=6F=EXL<1;DG,1GG0EXCV*?VDL@AZ&.?PZ MHV$&O63IYZ&ES!SXW?ZB_3LF^KMZ+]W^]CY#ROS?+[D']"2^D*TE]UA@0Z-@ M;)E<3%263QL.*=OGS%",/3;=_K&7&CDB[W6(@4QQ)YINF@\=N$&S9)$27$3; M@GW!!@#`&`,`8`P#4YW.8C64,E%ASX^PBT*A8,E))1(2F^Z;$0%$ME';]ZO^ M7HJNK^4@EM^4W;(KNW2WJ;9H@NY521W!7LLL@VL.K8-94U85X^A=P5-,)''R M4M@0>Z:X+UZM8\6#*,=#16'J/MW*"A`)H5%NCT(/*`;'`#R#8D:AK!A^'4L(I)8XB=;198^%2DSUDN29QQ0JQT.NQS7;31R_;"-E_""[)OLIIJN MZ2;[H);;Z>**:^[>>>B$8P+H6G[3EEN02N)DUF4PHHLUC]I`P[`M^;%Y"]V- M:-P*C]ZP9B")?U6/E4'+,41?*#UD$M"7Z/\`6,_5Q8:CK@U"/7I85BT2>M6N M.<+/%SQ#<@VB-)W^N%HV5R9PR>-6Z+HD1T7L!O$`Q)LNL^8NRK!QWOSH6(0]L81>P"GZ&@%3\RVP;)MG+1B_GG1'6T0K=PZ"@4 M77CMMI3D_49JNT1SY=N5UUW0/#(H53D-N=!]R2R/1D2@$22:Q"GWTMH_DJK#I!:/L'Q(Q&(S.W3@@N4 M=D"1A0H3_7BS3$7?@J?-PV_&.F+Y>N/AGYX!)2G:V[(NZZOX@R0E-['B#24! M^;Z7G$V,JJ*E9+)Z6Y+`4=#9F_>[*J>+N+,TL`@YT453?$7FBFVN!K=HA1C= MKLW,>$'0ZF.:^>>^;?F%'((8R=%G&^ M^OBBSLFN[=.%?JLNLHK[[OZ,MMY^N0N=SZ<*LR[XMK9KGZZCZ M;@J)FUKN*J_A^J2(VFZO&2^RG/J^_NJ22_D8U:>J;?UCE/753;0:5-3NE;G" M\W"]2$/.M.TKB_JN9^`97$`;OW\II:?`27\_Q>D&U.P=C<-\$$?$O= M?4ATKB-8NUU-_P`I5PSV25_"$4K-7A2F_5PO>/0^GG-'R`VI_77C\@2%3"7G M_ID"XDH2$0'],CY_8S_BWT*KT+,WN^WT\]6*@@$$<[;>[?IVS37WS74)I6*9 M_P"3GT4>3GQ/IY\3_(D@_P"\W6C>G4153_TI_P!-=+7M;8UWI_+^IV@):>-Z MK:-?K]??T0R!L&?GFVR>J'B7T3\#6UB%V27K$^I8&!<,\559HCK6W(O,T$V0 MU\UT<12BJQ!/-O?//I^-9\.C"#UPMM_;NNX7564]_I;J;;>^^X)J;RV_%EDA M0((";>,P884&::_3\+44/:#FWGX?Y:_1!HBBEY]//Y>?37^7]V"'V?BA95+U MN4&L"2'OU\]1?LV[Q+WSW^WSU-PFII_/^_\`H_SP#B9?O$50"+JF0F6`OC6, MC^Q;B1-U3!^G.5O9K/\`65`Z.K>'2"&PB0BK$C22K'S2L'$T;*CA09PS-R]9 MAZNX+D6*I(;53BVJRO%46EOCY$DH5'\15>T54U71&C^CNIN?;)@E'R`B>YYL MP@W2T41UT&R^BO'ZNR/K<5KOMLEX)]+YI[W7[KR9-5#=\7'9*U"O4K80%O;$K)L M(#QKP:=%2RLQCJOMA]3;B/RU?'UH][>;*+Z)_7?P315Q'>*? M>"&K+^7N*P9KZLTY+Z:%I[I_J&Y[HEW0'%4.U:_3\7ZM^1ZTNZIY8R0_!_6> M>)P9VXVT\V\\;^K>:([BJB=UX35_XIE-7/S6WG9KA=A1-<\P+.M%=VK5G7\G MZN^0*6OG7FWNOFB(#CCF/^&*2B?TVU53=W\V9;;:^>)EOPJ?BT%T)9U>*II_ M\JOLC$DK2^9"XVBCYOKT/`HRX_\`RH_#TYQYP-#F:2W\]6K*6].VEW#?;9O^ M'SWWTMK2HVE>O!+56`BY;\@/:_ M,-.0B2*^ZB3/4G4G0?5Z3SZM_'Z@H*)M&UN.N2MWBC/;QT^T:\[2=AIYYXX; M-%F.V^BXJJ7]*;?2FE?:I\6E%A>,>*/C*N%[)H!57:DDZE]C(MJ1G]><[6/" M.=*,^W+N_&;34E!^%HI1D4/BE'FJ?_ALLDLV5=K>?GDE7NJN^VXE3K5W3$X= M2;?_`-IA^70L;4MR\@\U.S$;XW^+_J=9^T>D`Y$]3G"C^GTY.\:.U6KIP[MB M_/*193)%=REO[^X'TO+(O4O-'&KY='9/?81ZG^:M>-4^BGVWCF.@MW3KJ,3& MX2XYLH.N[&DTHT6WD[6Z[O>4T(K1/=BQK.MG_CU%%B#T_P!,^,>RQYLKPI\; M8.Z^^+[+)[>IX+JXII7A/\`Y:CW$^>.D`72-RWQ#F/*\Z(6`[AX^#26VP\\ MTL&M:XB4($!6U9!"(-D42;`/9JO8,]=.&3Y!4N9GY3=ZW20;L6C0)4)/5:<1 M$\^187D>H9G0U`PBHYP;C1LC"EY8/!)P]J5;1F+P%S,I`2K:NP>QM50H\$5G M`7L=K\40?)M7+P;&VBR[;5;91141N6VIOSF=WXLLC@@P!@#`&`/??I_/W^7G MG\_???[L`BZ17?3<0LJ"4S*;5KV/6[:"!5U7-7F)>!86!.&8(>2*F7\7A[E\ MF?-#A0\.4BPXF'"R]D8Z.W6!D]PSZEF$/MIH:KD M2'*')J=QZHB:AMD)(M0T,M8T$8PF=G6S$TS7*CH@6,[!]]'S(FHU(C7[- MN$6FWG?R^>QKD,G'0,Y@EK.R](#*-L(00EP6GAEAV#'I_'YAJR#^>PV;2Y6K MG+Y:-1PQ(=_="<<;/WLF9@F_KK\Q`D[\8-`M:\K>/Y.<7R963)HO\:-CE+?Z M'JN#7O6/[`N23+T6A'=&TG)4W;\9M(;#*[AERO;`<^O#J,6#"$MY4RD@UR:T M57.@GD3=DHZJ-4).NR<75[Y32EI?-N3BY0'SH\T_)5UWR*$Z$!NN-@?*]G3J M\`MH6'UAK&*ZL)F)J.514$&GVH]G3D0:3DG+B\;/H,BO[CCKF.L)S7C5)P$L M`Z,*CH_PW12XBJ4E&F7F;9VGWV1TVO+YQ_A.I:WE;1%2F"7ITEZ!2@FD\I"K M0,CG:D51<.5FL73Z!ER4*@B,5]>.W2WV_P#BPF%2465=N4D]%=5=QA?A_B-1 M#2S>4IQ,9GP(^_[=$C;O\JUFO!/+H)7_`,W(^B^@#G0M@^)+?R353IOF`1Y" M]7"&G]-1NXZ1]\V5VT2_#]-%/?0T;14WPE'J[_\`UQ?E'^>]&JRG/X*;;K:.'%F'*^L*<6L\<:_A\U<$K M;L&*2:QR"OU\\V]6(2IQMZI_6[;?C]]VR2N5YD:K>9[2H\I@M_[\OOQJ:^?5 M7KVKVW_^9Y)F?OG\OK_/QU'T?=?Y>>_7Z^>?3Z;>>_SU]^E)HJX;[7]C^]/F M`^,#W;S17N;G1CO[_+S4K8`T/M]?_5[X4_1^Z^_^[;Z>_P#NP-%7Z7Y?.+<[ M&Q,/E9^,LC[YXW[^X_3]V^GT_7="5>+\_G_Z_2:__P!O??/?/[\#17^F MK^U_L;T.^1#X_P`O^'[3W/QV3_%]/P_;^FJ5>_B^O]GX?TTV4^OU_N^F!IJ_ M35Y,D(7UIRJ<_#]EZ9Y],?C^GX/M=S5R0_%]?[/P_I)(M^+Z_P!WT^OUP2'P M_)DD"K1K,]^'P'8L%,_C^GX/M4NCY'\?U_GY^']&06_%]?/?/I]/K]?K@D', M3Y'/FHX^^,B75I7]WM[,FTZLL3Y*FT5J,#'3Y&-P3TJ[")3.2*R661$>B,(E M1AE@&9CGI$J2@3&N%&KI-%XQ=?IW&J;T<]00?#GFB[%\W0=MUD=!AIIP M[-$B8`P!@#`&`,`8`P!@#`&`,`BNG/\`A(O_`,U+U_ZW6%@KSX+V1X[JZ"H[ MG")*3N^K:K^HHEIMNBB:G\I$QMN1=Z:Z[>#0R1%RBZ.EUOQ::-0P9N_*O%5$ MT6K-953338$F[)24E\[>Z!OO_NG#O'TXE<=>_P!!GT9UFJ:Y=HC].M_Z,'OZWMSLRT+"#N_ZQY0G+WA3DJ@=$5_Z;H(8)PN1ENB;!&^?31MM^Y[P:B"" M&BF[B*M_U.Z"8FI+"7=W?K9>7B6BK6E.3.,(8LTK.OJ3YRARRFB14H+&Q6!) M&GOOBB_CB3REU^B?24NMXFLX5(R(J2*.?4U%EG*GNFVW@DU5)EAPAN4,B1RI%X MT1::/2+)KZK^HOQ), M+(6!4IX"-5M'/K<1+JEU?\)F#H.]K\MF3EV%F<66MS3#F@%0F&EU MH6?SW*7QXMJ08-D8_K$J:M&RB8A=5@Y>D_7Q9RW:(ZC=VF_OZETV\W!I+%2? M9/[I$3RBQ?E`(R60C:\Y5XWC\58'2S*.2RT.Q;4=DY!'VK]P@(//(?!.1B6@ M)Z6'Z-WZP#:5DO!JR^S'M"?ULVVV`[^GFT%;Q&3UK)WNJ,G]3U$/I`Y'^N0.F^[T>U(* MZZ(B*-YC:+=N3\M%X?)35`WICIJ`=]]DT:PNBJ&2W-W/JE&\L7Z(C-'W!!BU M9](,N@S)DK8ENNT8RG?D-@U9R\`)V.2*3D*;!O?1T8B+#//7,4+'=@[!`L1#.B"3!LBXT1T&'I3ATW5G=W^9+67H M7,/*[A,8CWR`PSG>=QOP7^^+-4CM#'74\V9@]AY3]1$K(4?QR*Z%3/OA_P!U M#H^;,-]?!C=3UE^+ST19?TRN+V*$'D>(Y:U,`?D)^4SE/KJ$>#?_`,)QBVC7 M&-,DZREJ9!B[3GT`L"JW$*LJ)RYLV9J,&A(#*1KMKJ[W7;K:.D6^Z8U]7]-# MI[:G.;<8Z',V\.O9]S4Q")\??.[7/2U6QM^4W,T2>>\VV;T:VBJ[URL-'UE> M4PA=FM[/+`F:[5FS#7`9CSTT@.5U4LQ%R_;(L1=,S/X;3YAJGQX\/(ON3^7S MFJ_JNJZ(4IV_T)35]CXT&D\_"#?CULBZ[H.#T`_@>.OU>V^JS?7 M`=,X5*_[ZN;6GB2C]D_+UT5I(9"^K[JQ&+!71DJ]"QNY1?Q)5[N"#N'SAP.# M>*'?D5UFIK42RW;L%'RD4T+O?R-W2H_597W34:5"XG9M?ZC]J(ZY-FM7YJ.N M+5@4#C7+\AY4K"?!]Q>LWM&02RQ>JFLYU;!?6)/QG6'*G--P,HXJ5-^ZG$O0 MC5H M_KKXCNS70=@OLMHKL2"&;J/<5A7KWQ/7U!/0X7W&>(*^[KLDUO4UT@=-%]N/ M_DH^VHVZ:>_/[;S?U*LY=TA7HUVGZFJ]E-!_'!0;5;;?W^?NB+OI3IVS0+?S MSW\2:R#-<@EIYKYMLJMXHEL'_P`:X?C6_P#\TKY@Y:_,UQ-\DPKB079=]3>; M2H2"GD#8RJ%;]E7STZ+^JNQO\.JG5:%,YI5,>,N?0Y3_``6\BS6[OD+@5?RK^*%.AW\$LL@K/!]0 MP:4/QB@F-*ODV['6\:LLNO@+U]^5LU9R1[%U"@UUNBF#>M2;IO\`F#?XE2TV MAW6[^S3/V^RWX0:_L1OZ-L;Y!/E)FD<^F^FD+<=31R+0)NAO[M[^F9PBOZBB M$9:(:Z[?EZZ-QJ>WY?\`1]V]\PC_P"' MI&%KM'>]E5-)#557+,WC83X*4<6#;D"<`)[+/'WOXBCYH].:CU#6^Q%)FBK^ M'S49UU<^#AKP3E%K^>.+*-Y?+%CU7[W$\-G`B$=)$+2Z/Z$NU/80V=HO4&X\ M1;]G3:/@E='#=+W]:`$"WVR/FS7=SLUWW1V$;;X\$E[)$7/?BI^.,Q)BLRDO M&E#363&RQ$X5*V!"65A*O2A9XJ_(.E$9MZ?:^?J7:ZJNR*:&C?3\7Y::6B6N MNG@NJI8J:[./8N.0J^M"PB-1\K7<%)@88@U;0\(0B0!Z(BC9BR3&LF\:&N1Z MC,$@S'(I#VJ0M%JFW9))M4M=$--4_!F3<6C-H/;(LF#5LR9M]/$V[1H@DV;( M)^?V)HH(ZZ)):>?W:Z:ZZ^?W>8!Z<`8`P!@%=;:ZMH^DY(C#YS()2XE6T?3E MY&.U[5-MW&8BT-6=O6#>:SP?4$&G3FO(4Z>C"K1G,)TG'HT\7#F4VI178.3\ M:"I-_P`M+WR3?&I)'IE'04NB1P3)HK*`XV0QN1@2#4L#/`C#-$@),ARC%5=D M1&$F#A!XQ?-%E6SILLDNBINGOKMZ(8Z:SV#5K'W M*Q]ELM[[JEJ[,G7C`:VV5]\]\3\6[^^>^:^>^^8!']E=$T]44BJN*3Z6+ M"3EU&7`&MFS",2^3-CKYIN'T>+O"D5`&Q,9#,O#XE5[(Y6^!QYFV=^.G)1)L M@Y51%AN7QDI[9WRU<3T[>_M&V':\3`?E1+]SN++VLBF2$(\([NO6C:"L8\)L MTAXS38TFXDU@%[II/FVI(5NYUTCCT/'8[;,Y16 M3=&V[^3,O!S1V0%T8NES+5O)M^B-1!V;\KMI4*:K20\I3YC/)8H]\\OXQ=_/ M?%)T`-=$VSY@E&(+7$C^0`W&%AK9#<2X=FEBQE^Q7:,'JB#M$6*$_S6XA MU8ZO3,^",E,N2OD1Z$KRJZQN]7X_A,:JDA#SL;+3D9TOV%/-)3"PJH0--9&: M(2ODX'-)GX@X<$"CV1`'PHF>64,JCO7R;-TV$FE.5JOG%.NTV/P^F.,^;U=A>RGJKD>$EUXQ^\)0R;*+^>[:MA\A64 M4Y-L?WUO6E\_-=\BBZGUU<;4+9O1\5 MK(EMO_))-W:D%UY3YQ]:N_?KLGZSGVC7Q/7=777333SW'SY^_@:NLK\.GNJ; M>#E^GJ/^S>G-O>^>!?C,YQJ<4I_2]D?R$]C7[V;.5-%?_(4 M?UCE!YT:EXIOM^5JKK[KMOZ)JC^I_P#6E4KSLU_:8FV?]GEC<^IF?"'#' M:'ZMDN"_$NL]VW4\S92EMP0#\87^SNG>0.LH_=UQQ^N+"AX#]Z^L1LMF0>RD M1HTK'7PV,L&T.=TN"'%)D/-NV)96?[FP#9BT%N$1440>$-54AJO\74H4K_/< M_66,CD>":>)A@(81IYY]/-!@MBPT\\\_L\\U:()>>>?^[SS!Q,S@#`&`,`_G M?3137W133533;^6VF^OF^NWG_J]UV\]\]_\`]^8!K;^%0TKY[X4B49)>;?7\ M7C\"*>>;?7^WZ^.&JGU^O]_UP#1B//=!E_Q?=J/J`G^+Z^;?<:TACW\7U_M_ M%^I"J_7Z_P!_U_MP67RR/2G$'%IS\7WKD+EXQ^/Z_C^Z4#5!#\?U_M_%^KB: MWXOK_?\`7ZX&I\OS9&Y;XO\`XVC?XO2/`?&F^^_U_&LVYIIT>YV]]_OV=#X> MU<>^_P#O]5^OG]WN"ZZOU5>;_QYM#&+KW2:(MRKH03%O630:>'L`'X3054:YV(CI1^,Z5 M%4U<.;^OS[?H[Y(YSCG(W,U(EY`Y9I M*KHL%#AA9^5^W(KKH#M7>K%%=9)OHIL.53U-OER6)P08`P!@#`&`,`8!SG^6 M272N#<"7U)85S-DIF@T8,G%AQ1`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`/4Q^NFVK1=>$O5=]%5-G2[W;Q+=-\^6$?ASCBW^I1' MO/J>4ITO\E\@C`B,R;YEA=:[BOT/KF1>_%?UC"Y*159-U$-]S1>63/F#Z9_P"TV4M` M=QVROJ*&W'P"KV2?B_J?YNI%D4AU?-27B?Y>OY/WW1UZW^N_B6R/YBOX@^G; M\)O_`+-O%\3'@;:*B%F65[KZ_P#]KIJ))9Q[_,=%]*2B#W?\7T_HH-VG3_S_EZF/\_#[]//=//K],%E?_X/U_\`4EZ-?&C-;(WV_4_[2Q?%I(O/=?HQ MAUZE63#;\7U_HMV,4ZS=MM_-_-OY>+)N?I]-?P?3S\?FXSKC_P#G2NZ_='XJ M/DAH.3\S=L]!4Y*YQ-K1?1>;N-V-I6(X5>R^S`91JV(A9V6?+OB:K_:2,'"3 M]N^V(._'C51%QHX534TWV'IHP*M-UQ<4JBM>1]Z2WMJ&FZEI)] M+K('N/&?VI"*V97D-JA:M7@K9%[LJZ6BLX2)?K=//&K#]+]7`S_JN'*E[.7; MPES/A[1,\6^"2E0%W$%71R?O.;/(>EJ%##>GNKHG<*,_T7'?F*E'<+LZ,UVO M#U6WW;U)`?'QQILMX.T_4+I[.M_!'^(XV3_XTQ[22O67Q2T@F3MP?:W.QI"+ M@#[KRE'P3Y%^X[4)67%/S#/K)S/XO/IE$PE:RCUHV`Z.Q(DM.P?KPH_T1.?I MA*3HF(ZWL\Y^FE7\,][,AFW7=$ZF8XZDZ(OL^@JU@#;N^FW MG@&8P",;BMN)T?7Y>Q9CJ7=#1SL$&&A(V-4-2J6RR7'AL3A4)B05)1+8M*IG M+30:,QYALNU;+%"C;U\]8,-'3YN*E+CYR_)$75=TD[F-A:U)9M+V5S]912)D MI]#(]89"MY$/GT.!$0PJ4/(O*JKG4^C>YR$D)+&6LRBQ,B-,CO)$))B$3\>< M;&DP:WE-3$J?NEDL_@@P!@#`,,[D<>8%AH!\=#,CIGQ;8.%=E&+8L6U;)*KN M/1HY9?1X^\010766]:HJ^))(JJ;_`(=$]_?`-:'VO5I>PSU1"K)@).UXL':R M&3U@/F,=>V''`#W4;NR.'H4V(J200'=Z&1&S4F0&MV3C4J-V27W\?-?50C?8 MT2#=/4+9XJV35;64$L%C1AF0QNU?(4@5E+Z)22*MG;H_'%Q00>]*DY`/T8NT MM@@1D3*.'J/HYHU7?[:-MA8=K9Q-I,)KT]&S'/6W1U?UC?ME1Y?;WP+70.G) M9#[ND/FLS\A2JH^J;B;UC)6"";KQ8_XXDJ(%!>'H;RAJHX%JM5G`1>)7>4UY MJ41ET7VS&>?(W5,D.CZX`)S@G'-YX+O#HRF.>2M/1(RR;/R9Z1H3N0N$9&8C M^BRK%S%8BX*N'I9OLV:$O6>_A'P$IF)?9-R58/\`RU5@:NJ'#N>2K7IVC?0) M3:=[\[T=U;?-N.Y9JD<3%-8.3K&H2M"(1=)WK'%BIV66FR<>ME3B3<%=QD^S;4S/9, MSC];PBHE4I=^QYC)]I-#Q)VLC#H-!)89]'CUI$;-E8,*(S!^L2?/M\_<[_AT M4.F\5-2LSN_G6$?HE^.3F7Y7Y+\?L3@,^O#GF%0OI*)2*Q#Q&QXA=]GW)%(G M?8]4TO$8G&(3.N7XW1_C`*Y^A;`J"(>ME`%40*&435T%9N6A%P60=J%"]<6? M6)7$\-CUU/5&Y37?77;P9U7E4I/F_[I>A-K+XD>$G.S5Q9-6R MOH-OI[IJW%"V24>= ME-U?P^IHLAC1TNYW_JD45-_?-<$^JKFI^+(C_P"TXK^=_P!1RWSIUYUPJO\` MU+"05C19NNZI^23V\_(:^7#+F7CE/W\_=PW]\\W%^A;U5=EI7FY?IY#_<%MFQ?Z[IKY".N M+125_H.H73!F*<>UHJUV_FNQ\;4*$#W`NU7^NZ:NIB[3"V[;?UNHLIKY^+!- M26*:5W^I^MO1$LU/\='#=)F/W/`.8*G2FWJFBN]CR^/>6=::RJ?T_"JYM.S5 MY?8;E7WWS7?=1Q)E-U5-=5%/=]]==O`=53RWVPO)6+I>>>>>>>>>>>>>>?3S MSS^7GGGG]GGGG]WGF#)_N`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P M!@'D(#V!9@]%E&30D,)-'(\B.(-D7C`@P>([MWC)ZS<:*-W31TW440Z"INERG#*9\(_ M%1P'R;+7]Z\^\^,*^M9I(+OKUM+D[`MB2KH0]"U91'D@Z8N8SR0@M?-0T>#L M?7_@O[GNFT]WW>[+.7:BXU77559N59X68Z+J=7\&!@#`&`,`8`P![Y]?Y>_S M\]_E[Y[_`'X!H1ZJJOE7X_W16\"DGYGU_,^_0^/&/S/K_;^/[@.5#R_4$F81P;:=5,:_<# M1T5=`T4ACZ45-'H>V9QQTXD(E%JN0C!7>*M-)&@_-;2!WX=5:#AUI_&:45)U M/9S[_/8[81GXB.28'&X]'JVD'656*QP&)!-3%8]P=^E]Z:?V,W[\?5@`/ZZM/DB^0J$N M4OYM$)%8E+W<'TV\_P#)\>-+UHBQ"S]/7Z>?T53VF^_GU_,4W^OON!JYII]5 M[-'^>\__`"71;^OAWR)5?8'Y'\TA=_\`$L9(^/\`Z?V)O3E%7#1GK7\7_P"\ M69Q[;^_\#?3^7O@33^E^%7[IC]Q?+G$/Z\A5?Q]WHT0_\ZA%;>O_`)X./=?/ M_P""82>J>@`K=3;Z?^0\DWX-/??//SM_/KMX'T*J^R8_[3^HP/\`.V.>N\Z20U_DN1G7$?0$E`M=_P"SW5Q**7B%KQC7Z>_V MJZ&5$/-?ZSU7\OSW?`T/9TO_`+)>[10BPKM^,$Q91BZ^4OD*JK@7J61./N$I M*2%;2L:LNE^G_+QKTASONN:ZIMR4)(Q*.=54G9D'MSE>Y6^V[;=J M.'7<%<+2>GWQ#<:D^TK>_$(RBAX.;Z`);,_TR+WT-%46EQ_2U%2\-\Y7BD=6 MX91]`QIC8;RN*HJB,,+T=/I':)&`0V*QY*V2,A;//"$EF9&,CV7LR*&6Q5_N MY/EEW[]]J0[?51I[[^A55;;BRYG?DJY\BE'U> MQXZCTA)$%HU#N(3]7]`QIL9M^SH&.?1KG]1KN3AY^?1V1ZRT@2D=>(G8W&2T MB=R9;]^O8V=*M#3I%;1R+2[Q^I-83ST[^A2SC+L_F#YB.S(%T+13^SH@PXAK MJ4_<(C/)H MJ&:VVD1L(X`:W2;.22=^VET=8QOQ!W(-"&A%&$+V)8I!2K0NB1-UJ-"5JK$@ MX;SQKL)9LMV+/=`);BV,0EZPK^,E.Y9=GQ!U70+_`):G/7-!(U(ZW7^X0J6= MJEIS8;W9:4)S!31:7F+AD=W/?I(DDG":?[E6\0;ZZ!D-4Q'T'^C45S,.?^-N M.(2]#09SUY\5-Q0BKJR1A5C=6QNFB44,5)#JMY0ZNOQ$"7A(CT%%"PD_':O- M!7;\.*V];MBAR3K;K>[^NW#I=Q[LX\"*KO$Y;:77GT5^ANYWHUW:EB1"V('\ M/735H6[`&1`?7UQ757O+5%'H.++I.FY1M%IK=ENC[9BC0FW?/4BC`'$VZKQL M[9LC,A\F,MDI::POD'@[FZ0'VS9B:FEJWC.K MELPNS:I-4&:1H54%)0,<0;L6[%D@F.7N)VBEHR:)-G7Y2*7J(?1^JI\6277+ M^QL?^[A\C$Z_IV5\C$Z?7Q M,CK'Q[I+WWS=-/3?7S;T2:5BF?\`DW_^=(_[+VH)/_\`MSOOMSI-/W^DL,M; MKBVH_$G*OO\`Y2KJO**+4U7+GS;^>NS=>)*,_4_?4O6WJ7]#`U/94K_JGZN7 MZDS59\?'#-*.="%7\C\]1(YHI^=M*6M4PY]-'"WXOQ?G/)L7%$)8^6_']=_S M7AE=3\S;93\7X]]MO1-53W?:;7Z%P---$M-$T]-4TT]==$T]-?-----//-== M--=?/-====?/-===?////////////,$.475UM122V1.(_87,_"-AP3E\E!2> MEJ=OWZ%JL?%IK.(LWF2+V#(2+ER[!(/<<*T':KR+26@BJ[U';34U*FU_]RXX,34?S`U!==;OZ(?]G[8ME_U_5?>?6%SI+_`-6]@=2R89QY M4:[3W^:H_P"R<\-HY:K]BO[LIHLE*+KDZBK?;5!17?S3\>P:DL4TKO\`4_65 MY)$[4QP3QCSV1^_U#S14,3EVRWCE>P%(B/D=G/G'GT^C@G9\KT.6"57\]\_' M^<2DKI3\SW93\7YF^VWHCJ;RWVV\L%N,$&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`173G_"1?\`YJ7K_P!;K"P5Y\%[(E3! M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`Q9<(%D#)0:>$"S8Y;^2S`NP:$F2O\` M+WS^L:O4ED-_Y>^^?TD_?Y>^^8!6.8\&<.V'LKO/.-^6)DLM^+W=S)N?JH-. M_P`6W]N^KPA$W#I-7^?OOBJ:NJGGO\_-O/<%U5+%3\V[;.3E$6`C-S/,TU5_,]6V19)P.5Q"V:1).%-]]43E63+V.C=?R_-Z MV+HI:MO1O_4>*K]?ZEXN9\?-$9-:TXFI-RA'^[.8NL^%B7YJ;-&XXIV]VY.N M/CSC;;Q-)4;?M87<+95ZF\VT670&WS!ZD=H(IZIHJ/\`?7\S8)J?Y735T=-. MKR:OX-YL2CV-\:'"UO<-W$7A?5%M1F&S2&M&$'N*7][=1W=0J,J+R$*PK_[\ M`D=WSJ$38$>G#B/QWQAL)/.UG19OL!9JR#07]`IJJ52^E=E32GYQ;DY#?!5\ M-]/1RT+A<=17Q7UF3LM!EFD`IWG2_;NA13:'`Y1'_)?94GD$`)4^=,A6Q0G# MPC".[K&P[+>0I/Y(R8&%P":0Z?BUMI0H7+2S&-XW[Q;!^F'_`+(OX]UOY%*% M>R5/W^6Z,SN6^YPV6\_]3EM+[1-MW/GO]_CA)7SW^_SW!QUU<^B_8VZ-?%E\ M;$2W\6#<'\E^NM=OQZOC%#5O)B/BG]OYOA*2QXL_\5]]_GLKXX_,V]]]]VV] M]]]P-=7ZJO-QY%I8/2%+5EJGK6U05?7NJ/GFJ.L'@$4B>J7GGGT\\3\`B6'F MGGGG\O/-?IYYY@S,Y)0P!@#`/*^?L1;-R1)/&HX>R14+J^>)::'&XM%/W;7=PL@C[ZKX-::N(7+L MO-P:9_O;=IVU_4\X?'K,XJ)=_P!2TLOMRT(ESQ'T-O?Y^D-*L@2%WWB^;)Z> MZ[ZL)!#("[<;;>I;+M-TU/PAII6:O[5/JX7BFS_/]V#O&X/ZWH;O9:K0+S^D M\K/ABI(]5*::6O\`+1DYNZYW%V6@^\V_EZY)Q%G6#Q;WW?\`2IL/ZO\`+":5 MBF>M3GT4+SD@`=\1$=K.\IA>+7+RMO%'3:6]UUS;?7MSQB0`A/@LP1! M6M.KT2)MD9"JBW*J:-&#!08XV5'#MD!*39KH*ZVU%TN*6J5Y)'3?F6GG]!T7 M7M2%3XV3E8B.(Z%#@4&M&@SXF:/%9$0]#@7)8ZY%"6SPNLT&M'!@@XT9-T/5 MW.ZON_T&6Y4VM9\SLJ65S'&F\2&W([E50`W M_D+/31(Y=X2OVSZ%L7!,'H9,=Q=#42XM.*K*)XA\6;OTN='N<;XA_3M&U MI?<#:&AL7LV-H'V(B2-FK.1`76KAP.,QT\W8/"(],U'3;$B$*?;B)$=N^8+[ MCW[UGL@Y5&6H<&8IS_A(O_S4O7_K=86`\^"]D2I@@P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P#Y+H(.D%FSE%)PV<)*(.&ZZ>BR"Z"VGJ:J*R2GFR:J2J> MVVBB>^NVF^FWNNWGNOOOF`<6^[OC2YP0KQY;E!U-8=,6HTO/EV92LMQDZF\) MDI6,QWIRH#EBS92E:S\=P&TIM"8./D,_CKH_5'_`$M)2[I3PT0E"HO\@<@ZLK"4T5T%-[@%5O0/0L=]D7R'<&611;(* MQG%@4YK,9II`MRXZ2#H`8WC#"OI!Z>!%E)>P="Q9ITM-1+3 M^FJ<:MG//)?#RY/E)AOOZ:6\0\TV[KK_`#\.49V4:C:BVOG_`.;M$KJY]BB; M1;;S^?X-9P^1TV]\3_4;Z^?G8,Q3^IKO3]T_L?U_OC]B#OZ)_P"*'IS?W7_S MBT-OGA^4M-O_`.IMZ0Z1BQ%77W^?T_/%M%/_`%I^?7S'A'SH(7ZEXJK[)C_? M:ZB<_P!$7\4/9RJFWGT3\+67PL$2]V_L\_-56ZU-NYUI]/[= MO&S-W]//K^'W;WZ?4(I_5Z/^/GF?S]T^7>8?TVL0^/*A6R__`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`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`BNG/^$B__`#4O7_K=86"O/@O9 M$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P! M@#`&`,`^"+IJX4=)-W*"ZK%?5J]3163549NMFS=YJV=::;;;-U]F;MH[U15\ MT4];.FZ_FOY2R>VP'WP"*Z<_X2+_`/-2]?\`K=86"O/@O9$J8(,`8`P!@#`& M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`_&A4-#W M*'>=4Q!7F#H"6WN69QT@]EM33T?T#:];AS2):Q:KL"LH=+9O%.HOVW]] M`3L].Z>!DB%D1/=R5-*RIA*P@4,.SBUTGI<7MX/^GB'A\7/TA?'I#KKA?`_. M,-LW[G&+<#5F/9N65D-",E.1<9Z5?.(A')@P\D`LJX.1V"*@8^49.)"B^'DV M2C=ZX67:+I*CG5&I\=+?+D\1."7%%!;H6A9%:/-'4FFDEV55IZ4)[:+3.8GI M@X:^:Z7?MYZFQ7.J,D5/??Q*HM]%=]==]]M?!EW]/10;-]IN?_'U8?Y12O\` MUNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY_P#'U8?Y12O_`%NP M!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY M_P#'U8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`,&6B-UD MW\8>Z6?7;+6.G'!E5LWJ26>(E]%XW(8_X.?^>7CIYLT24.IEM-=M5//UPMGM M^#S;751,.3.?:;G_`,?5A_E%*_\`6[`'VFY_\?5A_E%*_P#6[`'VFY_\?5A_ ME%*_];L`?:;G_P`?5A_E%*_];L`?:;G_`,?5A_E%*_\`6[`'VFY_\?5A_E%* M_P#6[`'VFY_\?5A_E%*_];L`?:;G_P`?5A_E%*_];L`?:;G_`,?5A_E%*_\` M6[`'VFY_\?5A_E%*_P#6[`'VFY_\?5A_E%*_];L`P4=B%U@6#ABI9]=E-ESD MH,^.7M22S99).1R4M(4AVGNUXJ>^-`Z1300PU_%YYHQ8MM==$M?/$]`,[]IN M?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY_P#' MU8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8? MY12O_6[`'VFY_P#'U8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12 MO_6[`,&6B%UE'\8>Z6?7;'6.G%S*K9M4DLU1+Z+1N0Q_P<_\\O'7S9HFH=3+ M::[:J>?KA;/;\'FVNJB8.D#28Y+W:\5/?&@K1]J.9:^>^>:M&J.NN MB?GGFFH&=^TW/_CZL/\`**5_ZW8`^TW/_CZL/\HI7_K=@#[3<_\`CZL/\HI7 M_K=@#[3<_P#CZL/\HI7_`*W8`^TW/_CZL/\`**5_ZW8`^TW/_CZL/\HI7_K= M@#[3<_\`CZL/\HI7_K=@#[3<_P#CZL/\HI7_`*W8`^TW/_CZL/\`**5_ZW8` M^TW/_CZL/\HI7_K=@'E5BUIDGX'S0TW6*DOQMM1=+O;$I^&?8SLC[KY+B5A@:I MD=UQP5/I).'M<"P2X^2;^:S!C)@<(W&EBR`14)'VKN&#\ M>9R$&X,#!K27Q!X?BLE!LYI$%SL3=F`)88W,J/6+A!,&FL_,?NBQ6"#`&`,` M8`P!@#`(8E'1-'PNU(Y2,IL^)A;7E4+E]C!X.\(^>&?V'`TFBTJEY75/11M' MH\,3>I>Z%9"X%M".R+],6J]4&$M6@L.&XLLLC"LN[.3;B!*2.N;D#2$6G-8% M7_OOH.7AB&\DM-%%W6_Y`4_'A9IS'IR-6^\Q::-QZL,-`&[^0,3ZP4:0?M@A M\<^F3"G?D/XMCM;N;=(=`0]Q7#>SYA3>LJ!-9'*6+^Q*^'EC$Z#!$(R$+OY` MPAX,"-]U&[IF\:JI.&KE!3=%=!315+?;3;7;T9/=@#`& M`,`8`P!@&*.'0D8#%9')3`N/1X$/=E39TX0:"0P<6P1W*5!.2-_1="(WN&<2:L#VHF7.&!J) M-)$)B3J:E]VL=6WA4%;R<\$!+3>D?#$BN#P`,D[F'`V.C'=#3)AB3369IB0WMM/A@V^#7S3MF6#:]5U_84=E\_HQU%F%MQT"Y4?K M0,E-&90A'!)QZBCZ,2,/604BX7$(/5R0O1%/[NU8[.FFJX--)-JSQU)3UQ=`.3! M@7B3`V,#"QIMT2?-DP)KU@+IJQ&T^')::'R^+V!$H MO/(0>%RF&36/!9;$I,$=I/PTBC,B'-BX(X)?(^[(O!I46\:OF+I+;U-=LNDK MI[[KMY@R[6>4;'@#`&`,`8`P!@'B)$AP8<^+EW[(4)%LW)`F3).D&(XAHAK7U MQ:3)W72M&#SB8N%AL?=[Q^O8M*G3$09L>2IAX&S5)B5U)%XS M+#7#H:TU7MC/2?F"4Y=UOS?`I"WB@V:;%18X5>1NQX6;?NQ&KT/'QQQ)Q(B(K1F1]9B:6]GB?!3?T9]*VZQYWM M^TI_2M;V@%E-FUCL:UF,7:,SC51IY&)+O"Y6J'*DA3('+6\0F6FT0F#F(DSK M>)RK\,8)PJ,%YC*G[(:T1<*M`X2/`B;MX;*?H`_ZE%`2D^4+ MOF#!T+#AN+++XDANO^^>0;382DI`+NCTD8PXY6L?,KM!,K;_`)[NY)[Y5U4D M(VF_`-%9G%[#L+\<1B,TAR9Z'FS+=XV8G%?T3O9`734LKGT4OR63YX22KSF:22F(7G-F9%1:+U])81%`4UEHGT2BTZB)),U$YI'0DMC!A%%TW2+1Z M1C&I@*22;O4&SQ!-\->-G6B+MLW=):J^:+H)*Z[IZB&Q8`P!@#`&`,`8`P!@ M&O2J)QB<`7L8F,<`RV/$-F:KT#)Q`\Z$>+C7[4J,5=BRC=VQ<*#BK%D39;JM M]]FC]FU>(>Z.&Z2F@'#1I\?G;8*F?CSYK15Y:F]#\RUO5C;HJ*%[0M6"DKGM M"L)&,-1)GX7#4'+'LCI>!D0@^>#8.1=PCVP)WH-0F>C6,`%!\@'353-;^I-M MPX5DW_R5WCHN9,9,OBOZ&E9F$DT);4#9.V`5<(]9/21^8^'8C)(G\A)3Y!Y( M>I1%G!WK"?+R>32Z65F@UEY&M4`(UM%Y*WG1?&U]_N6$ MX,^/>S.9>B[/N*=FX:QAZ-4>4#1U>02P;!GP<'6WETSRW=':C6?Q2-.:Z:,O MW*'$!*[9F[3V$./),[4LTD*>`00(2JI-)+F799\,][=N>O>#`P!@#`&`,`8` MP"BUR= M>7&?NZWI?6T^GDT0LTFRHZQJ)JFL6U<3.F*YC<#IVJHI:!72%P@:^DB2#D1J M?/$C7>7?K;C!IU@_%W?(Z(O?X(O^?6`YC5K20!CK:)"8FZBYEF,(Q)K+0B)%`ZR M%5:WG"\TYYP_YV.S%'5KI3-*T_3Z954ZG5%75_6J9Q9'].L9T@L3$Q?0JJW_ M`#%?R%2.HOQVHC^:K^5NM[I^9O\`A_%Z.;NV^24<`8`P!@#`&`,`P,FBT9FH M(A%YE'04LC19-)(K'9,('G09-)!PB[12("2C=TP>II.FZ#E/1RW4UT7125U\ M\43TV\`X6F_CY[;'\U\6\K1Q3EB8U#3HAQOT[%Y+9]JU\YN]X*G6\OA5>L95 M':#FQG^#+-^DQD4YC>R$6(6$48#8R36R4XZIY=Z9@H:L&QNE$[J2GSP M^BX#2R=CYC3LG@E=QWV0!XJ;=D`8"2R-Z[>(&76J`$44,/@;`D0=+#W8J=FN M8*2\T\,]@M+"%3KKO7G`_)370T3NBV)G4]BV))4)C$:NJJ\8E25*1NN992]< M@:WK&E9?.X#(X,"'&)2])/!DUD4J-O9$^TCEU8+U_S#(*AK:N35>5>6B5)SMO65 MHGDX41BZ<@!Q8F,A4*-.GL8>[259BJ"#4FTZI<4]'-4MW3=U?FYUEHZ$[5I2 M]25SM$X?`_8#6L(A?D(KTP9D,$B&D7C0T(G&8:>D0>/R`U&`>C'4:#+'`0.4H+MRQ)ZGC,TO21]-16469:5;JW)#YM>4LM:OJ9$S&+4'.S(FJG: M)T4KT5J^ATIUBBQ],I[2L!JB#JCMD`P`^ M?@HC8L^:L6#%ZV$543:VC3'6(GS;?B;Y5?-O1S3O6;=36F]I(9#OX13VEP&M M:G[..2:R8R6M*-3:K2$IA-AC',;HXG6\;#%PTN;51-9")NB7R1Q-Y&S`:AHX M!$"-K3"F9G"M;9IWGJN#I!@R,`8`P!@#`&`,`I7>G+;BR.IN..D(L,KQ@7Y^ MFEDDK$-EFBC"=2V$R+GV[:RAD2$G!T>).20\!.+96/\`V@X4'B1+$C)R@K1P M7>;,"(TG"J5[J%QE.?)%$:&X=[07MY"R^L4N:"IF2=!UG94^E=26;91_5K4% M"A[EDE`4%7-<2BCZ\`02"U9<9-ORI`?,RXU_$*9RDLL;>`V3<5NF(4X< M2DH;B7ES*4;;"S?B;F0BV#H'"#6J1$@Q7"M057Y94Q3%_P#DW*\' M!U(Y:K"84IS;1-/V!)QDSF=7U1!8%(I*%8?;0Y,A%8ZP"[["FNR#57T:VT9I MLF3IRT9O"#9LD_>LVCMRLV2&7=M]2>L$&`,`8`P!@#`&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`& M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@&)/'P46#D9%)S0F.1\0VW>ECIXDS$! MQ;-+Z?FNR),@LW9,FR?U\_&NY722T^OGXM_/K@$;Q7H*A)T=9Q>$7=4,QDI' MQSL/CL5LJ&2$Z_U9-5GSS9F)$&GC]UXT8MG#QSZ@WW\0:MUG"OX$4E-]18?# M\B7L$/FLLDW2577530003W6666WU32123U]W4554W]UT333TU]WWWW]\UTU\ M]VV]\\\]]P#Y)O&BJNJ"3ILHMNVT>:(IKI;J[M%-O=$W6J>NWN^S93?SW71? MSSU+;;SW77;WW^6`?W^I;_J/&GYZ/ZOU'USXU_-T_4>M_-_$O5_$?Q?F?D^* M>^)^J_A_!YO[YI^+\7OGF`?;`/X443134554T222TV4554VUT333TU]VW44W MV]\UTTTU\]VVVV]\UUU\]]]]\\\P#"MI1&7NWNC.1`G>^OJ7FVK8N/7VU]77 M2:H>>ZI.-_?/5G*R+=+SWSZJ+JI):?51337T#.X`P!@#`/BX_`/@X-$DG+A5-%15U[[YXW3TW]W6]]\\3\V^N`?UN8$ID-!.Y0=H44U\W M3&[O6VI!37W393S;1GZKXXVU]TUVW\]U3]\]TUVV^OT\]]P#U?JFWCGQEZY0 M\>;(;.M6GYR?ZG9MHIJENY\0_%^;ZAJKOHELMYI^7JIOKI[MYMMYYZ!Y4RXE M8FY"HE!RIAFW2=O!*;ULH3:M5_?/$'+EAJKZZ0;K>^^>)+*I:IJ>^^>:;>X! M_KTL*&J,42),>/6)NM6`U)Z\;-5"#[?SW;1FQT743V=NM]==MM6[?Q1;;SSW MWS3WSSW`,A@#`&`,`^*+ENX_-\;N$5_6ZV[9?\E5-7\EPGYKZHW5_!MM^6LG MYMK[NEO^%37S;7W;7SSWS`/M@#`&`,`8`P!@#`&`8TP9#QT6_.2`L-!!1;91 MX3,&'S48+'-$O/JJZ?D'JJ#1HV2\_FHNX632T\_GMMYY@'Q`2$!*P["0Q$@3&B4=7)0@Q&M]E-4=7!!V@S1V6VUWWU2U5<*)I^J;:)[[:Z>;?B]UTWV\ M\^FOOO@'F7D`%JDS<.C8AL@1\]V'K+DF:*3[7S\'UV9J*+:Z.O//S4_KZA[O MY_6:?_KZ_4#ZDC`@/HV5+E1HI-XZ18-%"3YLQT=/G'OOC=FVW=*I:KNE_==O M$6Z7NRROOGOX--OI[@'W?/V(MFX($GC0RBN^NFO]_OF`?5LY;O&Z#MHNBZ:N44W#9RV5T7;N$%M/%$ED%DMMDU M454]M=TU$]MM-]-O-M=O?/?/<`^V`>+4D/VHV_3:ND/7'ZE%N MF[6;_D^;_F?GI-54G*B7X?S-&ZB:VVOB>^NWH'\,2PHIL\U&$QY'8<\5'D-6 M+QL[V8OT?-?5F+SQNHIZU>)>;:^JME_P+)^;:^[:>?7S`,A@&-(&1`GU#PJ5 M&C/77N^K;P@^:L_7&R?X/%/$/'*J?JWNGJJ?X_$_Q>Z_F:?B^GX]?J![-'+= M199LFNBHX;:I;.$-%=-ED-5_-_4-EDM=O=TM5O$]_4O=]=?%/--_=/KYK[]` M/M@#`&`,`8!\?U+?]1XT_4(_J_4=G/C7\U/]1ZWU4U2V7\1_%^9ZCJKOJGLK MYK^#Q3;73W;\7OGF`?;`/%J2';_B_`_9;_@561W_``ND-OP+-U=T%TMOHI[^ M%5!=-1%9/WZ;IJI[I[^:[Z[>>`<[U^?/DF466W1^1ZKT$=U5-TD/]PR.*_DI M;;^^II?F[=">;*?EZ^^:?F;>>;;_`$_%[YY[[DORO)_N:FG]/JREOR'\J?)5 M,>(^EHO_`+XT:OOPW5YEEM34'X;$AY=8VNZK7;:,@"0NZY$0:$7NNOOY*C0& M35]\3VT\:[^;>^^+\KR_DM-5*J3TX:WZE`*YYZZAFO8W'A:DP,$1S MI?I/;^34I*J8?DK_\`YD=7_P#R$1K_`/Z%Q?E>3_A3W/[CNH:0CT(CXQS$$A.UIM:L_;DLF_CZ&0FPYA4 MT8E#@9'8/:,CT2#/GSYZCZ(:\E-IT;WG.+V>6]]*GB/R:TE3=KP"@!7=:]I( M]/?)#8P.9[1F-R*+GB25K"Y+S>+T8>T5*GLTB%E0;-X?+.W?(\0OJ:R3KZ2=1R&QI!$I/=U@5M5 M=+6'&H6PM-V/*?EOHTE6TSJFEX%&YX&Y8C?2G)QBLOL/MWI&$0`5`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`^!8L1& M2,%'Y%4=,6-%(RF<(2(`R`VG&2\T3?!";]*7R")/XNJW$JB;<>3XRY[IQT1T M7P9&`,`8`P!@'A)HOG(T@W%ODQA)=B[1'$E6>I!(>^504T:/E&&RS;5\FT<; M)K[L]G"&KG5/U'U9+S?\>H'/@;S_`/(ZW(L'!+Y%JS)#D'K59^.2X3CC!5^R M273W=,DWVM_N-F2CI#51#1WJW7V;;*>+>(J^Z?@VE^5Y?R:FG]/JS3OE1D/; M]=4(:M'BZ=G4I4#9#XW_``DA?,+OH2:3(S,I0%CZ4L'NA$A2.Q837P5^5DQG M8;#)&48M(\07B]O0%V'M,H8VDI(\:5BMS,$F$R50.ECEHN/&`/5 M%3S<:_$:<56G#2%M;P1T<&T!\CKM5B`Y+A2.#U2#%) M=/=VR3?ZW^YV9*.D-5$-'>K=?9MLIXMXBK[I^#:7Y7E_)F:?T^K/\^5^DY%T M;PC;5)QB.R>4D+!F'/`EZ'ANJWLF]C#;I:GRLT)B5$-%%6JP"'CSI]5_JGO] MO:C%WVVONK?;S*2EPYXGV9Q?>4%\DAV-=@\SSFFB=I3?HOH7EFB97P8%4TQ\'Q:5NPUDVE(APH.[W'>-V[GK_ M`(.DTS2T\)N(F*F[))V<.ZZ(P-E_';-MNL+,XFX"@?)D^AD* M5E@+EF_:XK^8BY&N#Z?FDD+R.J&58RDA!B=6];;BCT2.7K.''4(F:>6>P.>PZN@K%*$O1R>A589FG1IF[4X M4:LJ\SCZ8C+V*_5=45EU9;O%$+-<+W=#.O(;W.\F'3WR,CJR>'XQ9L,F]C6N MTEK"273#&9V3S:OKKA$C@84(,D2VT2KIPZ09SAE7;2#CR3\693>JT0J)PX6V M+9Z[2V7B[?I%B8ZWO.;=#\)61WQ75C\P5'7O)`N"QUF>9U794>E%INK9BZLR MW,#"'-$EGI.0U;)DNA&.X90>$C?Y;.6)DHHV"K"4OZ4E5IESR M363_`"9,>DIJ,B+3HIGZPM&5"HS#D8G!)%R2TXW:8@T-[U#G]`M4AC*,>J%,<%5;#V1EBI7)%ZY* M$'A8H]\>)`]&+6UP[WC\N^_/7I!7CGGH#Y3[=Y_ULJLI5U+8S.5\[QXS:DJE M%6U&Q=`IJGUK`XZ4<\7IJ0@(#L"6:\C>7,<48D=IF,]FH:#_`'/1*?.]XRX> M'SY?^;%J5"J:A**K7;M#_-?&J/"22;8G/RQC:JA!RN''7IT*+N7I#^'((K5\ M1C=\VM4##VJ5J%2N:3@ZDL;2I;#V,ZVV&AJ=H\_-*NE,-="#5\'X@=&C5"HB MT3>+Q.Z69B]]FX6]6=?6]&I0/N_Y/"=6QZ+0:%,JT)SR M:<^4Y[S));A^SQ)(;)2V+:5]O=L00B=AMM=ZZBZUBL5-O(56K\Y M&4+`W,*@R+^!C&[5ZY.A(R. M"K7]`H2T*)>K+,4VZH+JIZ&E3F!7T MDWS1=I(/`/L@8IE#8<>*6%I:4[-J$^+J>TJ5/V9B/C6I.R(;='8=S@*S-\J< M>W7+H40H;D&4UW&J]D(*2Q^!14!8UUK0V,GB3"K&UC2,63\3A'K$67/:(HRN M2"`S[]+J4%J::I4S4LU3.[A3O;OP="8+!+W!`[58SJ_AD]-RHO(7=5G6M/`X M@G4X@@T<(QX.]$LI,31L12.NU&[Q4F4DQCO9=9R&VIY.>>@\]JGT`+I^^Q9.?6)07LH:@'4)1-' M(^.>`EI8BR1?$1VWA#\WU/ST:IJ2=3NII:4.\RL.#E;7G(KFNO>.1'47Q_V# M=D-JJR_DZ;WK4$/YP`VO1\>G]M&J,>UK(><*[^T-8M%N?I8/$/2]2[))LW<0 M??N@:2((FQI5UZ-ZK5::HE40Y:=DYE\K'&(L?-?D3H6"5C62/5G(IOJ77_<. M&U'S_%Y?3CSLR.\QV7Y>]H2H_`)W6L8M.#R$5,CU`2:G:[$7G%Y^$TC1:M-Q MZL]:#`B&AQ\^?+A-2VJH^J7#TRH5UM9RX:WQ)TAZFIBU+4^+SDZ$VS1]@LK' MBKGF*06G6M)QR/\`0OM3&X9&_/'^Q^F;B.6I_O05W"S^@\1**X+RZ7RX^BHC M,$),7-1GU\X&$TJJFKKZHFTSUM#C]MRB48A_R>03FMI%J(A5M4Y-3-C[78ZIMU:<&D5BS!WSG%Y6-%"&:3P8*:@( MZEM&FPU]&J\9I5[VAZKJ)V4Q._5RQTD>^5*!5];U;5D2[$G4C`]$=)(49#YPI&7TL/G0F-T"9UED;E=Y2RU@<4+I>U=7@SV)E(_8$F?,F,7"+ M"+0VIC"E7_4TX^KB'OFR-`-7[B!\[93&7ZVG'AD^:"(#[$ MKB'7>>K^-O)E.Y;T($JRQ9[)HZZ>QR`R-U(2K`@+$=W>M57<;VB=\3A*8Y*U M/.A/E,23%U`_F/7J'0(KF?HZ>5-$(;3]=OC4YL^-]ER.$\Q%[]1D]=K*"JH. M50YC+&:251.("W071-_+3X\]LKX5%BC-HE)MMXT_5%\S,9O$6.D_R4\9VGV- MT;P@)80BDRL;C53]EL+-EMZ\\*],TW`3TW#<[M8]MK"UY[6VC*9DG(62J5S( MW4DU4'N`A!;P<]V\4U3$HJ5*JS,TPDX;B9O#MR5VAO(W6_)=Z[>4;->@)'$Z MZ)_#S1"YGV/Q@E&K]J&(G)+672\GG.I>-R`RJUKVM3CTPI[&I.'3@7ZU%^Y= M%7#(-NJ9'\6G'RXS<[9@MOYUY6T>GDTYB18NI?"8+(); M4>Y;M3R)7ZG$Y*XHB$04B/`\VE6DA=J!8E*:U;A&29:/2&5.QDD+K!]%L.)P MVD_I;4J9_-VS&();ED#^3I:RY,$"7OU^Q@#>Z^I*R#/Q\9IY;=S2M=<@Q::T M+/M##VG':^\CL;H\<\C3V8I;)HF]GI>*Q\>!_6;KZA-'"PG,O.J]IC&W3J:T MUM;Y;BM[4`Z$0V_Q:_E:U(,M,%-HE&E*%DLDE?#)Z52:1.4@M1`&M?:ANN5P M$2D[4E;*B(=6;@2.=A%,.ZZ1G\TGS5D535<>LP`5>4/83NQ17.0B!U)*YJ5K!GT"TK]K)2S:JY,& M0&/![&MI&]A+N?F`813+3TXM#?*S?,3][DQL+/\`E#9RRNJ^F\?O=\+M8%'X$[6;!NZU)"5'MCT;A)I8C_`-ZED2^Z%20--_L4AFFL2&O2 MK,/H_P#/=S/]/S')4:F*Y^1&HJF;[P&$=$*6;"^;+?ATKG,TJN"DKD'%S/R) MUI(+%&T],9/"D%9@8)\U.K#L>KPBS^01>6S?30RT8'"+`.T;3PYXG/SP+],J M<3B?]MI4VO9XL3;T!:'R.L8M3:'.`CY"WNHG:;R@/+;:KJK=)!.&0OH6.,1D M4M6NH-2Q4HU4TIQ*0D8V[M:44^5,PS;3QW"Y1:[EM^EI$J9IH(Z:^J;[[^^ M?BVV]]`RF`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#%_8POIKR2^A MQ?[CU%[`]3_V]I]Z\"[.]7^P?PK^3^N\%[/M-'NP_P`7_2>N]=7/J/YVOF_@ M&4P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`-?VED6TVVTWDL?UWUV]UVUV,CM=M=M M??IMKMKZY\]\V\]\]\]\]\^OGO\`+W`-&LRWP=>U[-)T+&O[,(1"-&)$UKZO MB47>3B8J"&2KW]OQ)D=D`$4^D!'5'9N+8NR['QZ[V2:HJ^N%DD]P7EW.?W,' MS$1:8#YI/GI\X.?1YM*Y9)U: MBC,1W'N+$<6!$YSX2B(N,10I(DAIT.E2[??ML[7G$1>;'3G]W13_`!/'O_C0 MW_ZG!DTBT[H@]2U):]S&WBAV*TW6\UM&6LXDJ,,'E8Y!(R5E1=`4S6),6:Y5 MR.#NTAC=\1'-7+SU))9ZU2]W73%2EI++<>95VJ/DHY=N0"QE\0D)S6$N.3%> MRB,S+#AK,!&JK&R621&5!Y+ND:=$1<_@T@B,D'3&/>CEF0AR(>-]3+ERCLCX M*Z6O./$CU#Y8N<"'*%7]9AXM;I`#;UQ;\_1&J'H6"1&WFMS(E)<-BO6Q!P0-B![P-+F.D^'SU/H>^4.#B5:U%C>6. MT95,;#J"R[R>UR%JB$C+!KROJCGPBM9R3FL8FMJQ)V]W:2<\'^P_PZVGS2:A M20^0PIY(`I$>]=!ILW-,)I3.6U.R?C,&[23Y,^58[(^+0"4CD4C;=X#&!ZE) M-'`'CN-BHV=\A[*)R.S7#Y^.)P83,I98$,KV-;.Q3MX\GI]M'73-DJW(+,PT MU?5;\MGZSY0Y-?G7R?4E`IY/`+ZMK\,U34=LQZB[BZACT)C;SGRJ[6D3R-#= M(K*C+N<,+#=I`2TPC0>8R:*5O)8A$"A5%I(#['=N_P#68:7$RI:;2O+2\([7 ME[&^=3=Y0;E>PH%5Q:HKNMN8S^N[+M9DPJ%A5BR(2"U,1A@N8F3SRSK8J]MI MLV=SR/\`C)@'W,D'NBCK9-KK^G^FX*F9BJE4-GZ&,=+C#B<^B7L' MC'4S1FNQG6/.1^VK4T7T59O7**,>C4A.OE68T?^H5#35$P\QC=_/4V M]_V?R`)A4$LDKU-SP,KVT"[P!6\X(7-7C*)SLX.=>L28>)2!S(4A4@)BGOGK M,JQ&.G+D8[\];/TFZWGNF"0\0Y65#L:77O?G*5@S&X:[\N"#0BP*.EUKQF

Q)O`XO+D0]+?D[3RS&<>4E3HK_"P8W45>;3(FU&-6[)D_=DVXY%HKMX+I<) MQ9Q=)Q?;N;>GVKQTM`Y;::'5?.:]9P(^SBDVL%"Z:Y7A<3E!+1%4;')#)DI' MN&$'22;A#<<)?/$7[_55/UH@M^+S!-+LHFP:7B'*RH=B1`UY4K(B`< M3'[>K$X4D,NE$``#0\]BQ)^;G<($NCTTA8AFR*K.",KB(-B],R:/,TUBP$2T M^/OG0 MUTA8`PY8L;"2:*QA>,UL_B[V4KN961^VM'2"!LZ(8>M&BO\`6/-MWNBFJ7\T M]%-OZ.#5-+J<*)ZE*?C<^>7F?Y+KGF%*5I6-MU>:AM8$[2>';54@#`"]%BY7 M$(FJ)8J@)B;=[%UG>2Z:1J# M#_1XM8P*;/-FQ65#G;YO]Q2=>#$W2K)!Z[U;LG(J4N%N1/(?D=YO!0#HZSVK MN62N%6F-,-!+1S7&J2^IXB-@;J5IE/5T+)-1**2FP!,9\$;I. M8-'R)W8FEY^D;.A-+TZMICY\^Y$<$^3ZDI_/($!8UM?@6JK=MB0T;3?4$AA, M;9\^6M:L==R4=O%HH99S?;N&'KL'2U M-U*4M;K'2'F\-QN?UTO\G%/\LV785>SFI^@I.)IRMJSMRZ+3KV)P0]7-35_: M\IE\1B\@EGW.RP,^>(IDH-(URR$0@TK,+HB\]@,\FT$CLV&":&E9"(SZRMHUY*GI M1K5K9\-P^7RMQ`XI)VUVUNJ"DDW:*AD7*(O=-D/ M`AVL[XL[]N3R(]C\CKBZP-H]0<^JA[L*NP=/%-+BK[UA:)H>30"$!$`=?N#\ MF6$V!QTU!OF`/=ZZ9FW;0.Y22).D&J@:7>SMFSMO?BUSRVQV7RW2E>3.SY_> ME9#HO!1MM/C'C&9QXL;=O*+6]8VS&H^`'DERTAF4%->MXS(XD(:NSXF4OA\< M?L6Y=\V:*`J6W"3FWKCS--"_(!R<0CR3FSCC MG@WF0]A\NQT^M"U+\J`K8^U>O;2#U8#LN"D;*E4(9Q-[.4CD4AWDA2+'&)2) MCW4@$/&J7K$@&2W+I._M2:SU,335F'&)BTXR253-IQR]*>JB[8>V+LXE<5:P M6TXLTD#9JR/-8Y8,7%RT(V-LV+XFQ:%T!A=JD2;,R1!J@\U62;OG:.NCA01V ML25@#`&`?!RZ;,T%'3QP@T;(^>;*N'*J:""6OOOFOFRBJNVJ>GGNWOFOGNVW MGGU]\\_M]\P#"_NZ*?XGCW_QH;_]3@%(>^ODIYF^.JD=+ONTV5D#$G)&4.B, M)K9,/(YO,90_9/R6@\4Q>F@XIFS9#!;\D6,FBXT8Q;-]4-5W!5\*&$!JFEU. M%_"[FN_'E\IO+7R3U7(++I0H>B;R%GF\;G=>VB@$CTTBI)\TV?"G*R0TX;"E M`9QLB[4#%Q)=VFXV8/VKQ%@09.F2(54.AP]\-8.@'[NBG^)X]_\`&AO_`-3@ MR5VZ.)+HJB[_`$:.K535951`5*9NE"EMSCP3>Y5=M\LU3&M:Y%0GG?K" MPK'L&9=&U^YIV)0JJO;&@4LY6>0MI;XF9(R"Z`$1<;C/W]'5Q"\%ETV;&DEW M";57]6W]:[#6AWNH47O#G&T^<1O!G7'RI4@>$U^_HRJ.C^H"DWIA/H`G$:*K MR//I96M6[R(Y#O"MC#;$G-("OM;]L#6)O9"R*L%`[4>BS+/A=+MU2:6]VTO8RE1_(-6-B")5* MK#K"\^58%&ZYCMO-+.ZFBD5K6KI)64J?^#0LH86(+G,LB4<>+N56/JT%L4M" M+*:MR;%RO#=$-G"C<'3LFJGCZ9=_*_=2NI*#GM_C%F+@QMYUIS6T$6%:-V4\2'M601$#3[*KU5606FT8,XFA`^^M*U*M%,TTDK M!!;#4[>_ED//TZ/K=+QP*J93-L?:9LJ[K0 MASG673R\_MJ10"O`8*NK6DTLB$<2E#`[-4I3&R21V'D6*Y0Q'6D%+.7#1C$9 MG)B29-D.!TM;2Y=-KW4?OW,[[W[QSO9%6U>SZ'J@F=N6H;$O6O"XN=Q5]#)! M6%7N$499)6DQ0,;`%V[9%*2$VVC5XXW7"U_9!C;\H=!)&Y8AIJAN'9I.V[^> MJY-E==L<<,:X`W$]ZMYR9U-*)$XB,;LQW=5@-^=8) MH+KOQ39\H^8MT%W#M!%!%1342',0Y65#E&L0+O3EF>VM:U(IVU"XE:E2SN00 M&LLA7M"^5(RG36OEBVUF_N?[5XKX<=Z*^./$?0?C#153T^/1$'@]F%NJN=!5[+P/YZ\ MP(?#Y^WN2U@A0%7XIOC-65465X$Y#W454W54W]Y^K+SW;=3;W;?;WSR.>>>? MBV]]]^GGGGG\_P"7F#6NK]57F_W-#LWXB^!C]>34'5O&?%E>V,7C)@;"9V=Y M5K*<"8?)'K)9N*DCV(;-`"4C3#NE$WVHAP79M7BJ.B3O95MZJ@J"KJF]537& MIKU*`\J=`P8T:/(3"M[^H6!6`S*0YQ7D691;>*$7RFB M-;V``MP7+9F5.Q,2A#Y-")LI7RL!&J1:+20:-/\`%J:BZZIM;[[NULYO.QTX M_P"RB^,G_P!@+D+_`.7^L_\`[Z,I/F@U MT91MBT?(I_5E0Q$&5:B)Y%#4<1>$6D?2C3B1L03LOJ:3`KF1[=\Y:)I>O&>^ MVCI$-54IMMPT[MO!1N3?"!$G\AOK:&="22OZZZ>JJG*HN:O!$'_4)N!,5L"- M3"^WE>FO)VQ3@2O2XR.KBY6U\"'T(](99-IIK[(GL@V&M1K_`%':4FTVT_"W M]KNNT&_//B6+1J.7C":IZ67)"LNH:A%]904Y-0<,*0:SQ=M,9S- M@1*RX9:PU&`&M6`XE!)1!Y=78@T+EY1H]=!]!-=TVL*%#TM;J,XOYFL5G\2] MQT)I4Y&@>R(S`91`Z7Z)I(V[-\Q[S**I1CHR\0%Y%FE-0S6^XVSJ$'7I:-"H M[6L8*/[-%!`2'Y1#PMMM[I@.N9E9:>>%%[7G>(N8*4?!164FB1J*?[R%U`$8 MOS?1/.'-SB,/GH%O4`>@$=)?$Y9.0PV2-Q%U'WG0&B5X/T'C6$#FY)@&CPI! MA]I;'?05?*3EMOK.>UK;GTO3XFNCIX&M6"5IV^%B='WK;2=_7=1DCYX9EA]E M6<9(U](;,"-K*966WDU?UA8LN@6LD3#"`AR70Q<\:&CIB7#/%1^XJJIWINE" M3+(=W?'!MV;;M-VUI*Z!;J5/6MLUMM!^C^31/5L$+HVH;KHTI*QU]JP#F?-3*FK&0%D?-$-5=]5AFFK2FKWBZJTM1/1SD@X/\.I& M(,822B?4A^Q>-D0TU+/V3=5J+KZ6;JF.*M.+.'].;S)K)_P"$_8FZ:OLE$.U[;\WAX-L#?$M8$.\`3"`]-0\%HCM5FY@ZC<%OOHRRI`'G@'VGHBW%2FQK&M\)(?-S/DYASCZ8NDUI3W2ZO"71FU3?XE&$O0EZ25Y^BEI;:G=]FN7FM5L5G&F_;?.Q MOG]00XU9382W=;5L@49R?Q^B@Q0EWVEL!3%1)#\@BT#7TVI7]KGU/X+_`!1E M&,Q"VE6U^`HO9$"D7)DOK+]STEY,*X%R#F#GBR><%=9K!&5I1-W+A,WB-G%B M@U(-*84O62TODL&93X"W+5K+9;>YR,LJB$F(ZZA$>!@U0MB.B M#)HLS#7M%I;ZW25GV7&Y5'K3XL^I8K#),'YPU<7;8O1M&]NU7?TR;1RF8G7* M!_K>TA=N+_MZNK-N.,%:2A`R8;*_DR:"'^@9@RCHMR@[@AR8.`\Q9BTU*5-D MG2UF;6RE=[WCNE8OER_Q'.H?\@]Y=)3"+%X95`"$@X_3,8+'X47%RZ\9I"JW MKWH3HB+@XB;-O(F,ED"H2GHL%;S38/+WKM]8Q)]&@OAM=8L(VM"67OV4PL7S MU5D=AL&!@#`&`8*4Q>-S>,R*%S("'E40EX(O%Y5&)".:%P$CC9\>X%'`)L2_ M278E!!<8[=#R0YX@LU>LW"S9PDHBKOIZ!1O_`+*+XR?_`&`N0O\`Y?ZS_P#M MS!K77^JK^Y_N4W[O^!CC'J3GHQ4E"5!SKR'8A&21NO]57]S_<_VP?CBYR=<]SCGWGVN*JY<"6#85*6%)GU65/&A;(P0IFW M8%:+-,P``+1-(LN5;0G>+H/W9#W8*@85(I-WWC;<:\#4YEMO.][KER4S&_") M"PAF?QR/=$V#%.>I]U97?3FU0Q$0\CDIB+.I(A)=*SJ&$6RQFWZN.0>"6V;$ M6;$]V<0_5@1<+B<#&:-DAODEV&M>[2;AJ>^6URU;QD]AOX>S[:EF?/L/Z)@\ MKIV/6I=\SA]8=5GX0*B%W;"#JP4JB;LV&RHA8U;V%[.9G75L@99$EVJ% M@F8Y(HG($FS4K@FM3,.;7IJ=+MX;[^YX-?AUL$=$[!J&/]GD$:1O'FWF[F&^ MADFI!.77+-8)S]$I'"W;B*V\\MQD$A!*P`R_Q"#"-LENC&G2]FBN@->LH3TK##K9J5VJ:+QVND M!=?Q&I']-?OE-A)&S/G-L:HU]-]Y0)-/FDG+R5,>S25VC*@FNT0HTQUYS?>^ M/W-0"_%'?$+FG-\;C79@\[QSS'T0%O"O>6Y51;%J:T2&SR9342/-7H%GGWHT M0KAW.2:D#W1A`0>72$QT7.VYO0,0@MS.C%7TE7T(@<]@+$VPKPM3\LL^6*R]D2)%GX\TXE#J?B=/1;R+MM M`JT.9O4WY%1_XF/$U-4Z4VKMV>927V?F0++_`(I7IO>0$HKT:]@4G+V1\BME M#Y0'JD6]*!BO?`M4:BFGX0F:C5ZK4/X6&^CYRA^.<)#FZ*:$*52;.6HNI6M* M^E-3G2Y>V_IU/-S7\4+RD;C@UT3*^F=G'(G?%MWT[%JUW-_4R)ZV.7ZTYK=" MV\JM2^[JGGT!MZZ\EK8]))-*S3[[VYCJJS9LS;D-A'5*B-DO)NK9+DTD/\+X MD16T?K].^T=U@/-_.W/:9_2GFR"RWE#=DN^O'$NU9ZV+OLWVFY!SI#W0+5^I MX)7;Z2[PB,E*SB+R\#"7;^K M9016B;UYV%5?8]?/Y$(D%]G8"6!0^5U:.@TC@E902EHI/HD]7(N&8"7+F#YI M\^?/6Y%7"2BUF[_[72\)1EM.\.,FRVW\0\RO.516P;,Z;`$9@3`S*%7HQB5+ MS&J*XGL%EMVB[K\$0F#U#T5`5P9D81';@UI#=LCZ/]DVR[26RD:5EH(,1:@J MXV[7O,1=QZ+2?2:?$#(YV6M\>9Z='H5G.T?DB_9,584=LG*X:^^2=FZ7L%W( MYLXMQP/FB-<21VH1A;,?"H5L]$>JB#;MP\40-M!=>+76G?\`2[;&:6^*^S6\ MV:WB!Z>@['H`78E:V*'-%^;GDAIU!_%>+4.,)D-*5,ZO9`P7:2B-^OIK&7/E MDCWD+,+("'>\N&ZD%"0BJ41%H:S?*>8Z+:_E&+E/Q)6#,KB@]CR3KU8O&X#O M#B`.&J4TZ`M&9<#R?)>73V@B,P*XH51,<"R#:4EK*:_9Z(1F((D[]@S6;+P% MD,"L@U9A9_\`95=WB,]?^>Z)H?4_P"RS6DZ:K"H]93L+\![276M MX0#AOA_T+X1+^!_3/@;[CZ+\+%/!_KG])X1>_D_J51AW;?),N`,`8!H-GU76 MEV04[6%PP&'VA7,HU8:2."SV/"Y5$SFHHJQ."_"H$TV>#7WVXT,'%F/KANIZ MT),&;U#U-PV14T!-JZ?]E%\9/_`+`7(7_R_P!9_P#VY@UKK_55_<_W M*:=S_P"S_<$]:TDI7%4U/5?']B#Y`PDD8M^E:=A@XD@X:-7S!R!EP(/Y%5)? M$";4BHLY"^R`,X0+,A!1H22]8K-7HU3^)52YEU=&VS7^!/\`9Y^&.0*I+Q"Y MH#6W:%D28]J;.6;=-.Q!RW&-V[35F/CD#B9E:8^Q($AK^>[?^>R$J1-%'2KI M\]\:-Q0T8%7XE53E-TKA-^O)>O\`[*+XR?\`V`N0O_E_K/\`^W,&==?ZJO[G M^YA[M^,7F"U:QH6BXW5]15E0M.=*ANB)!2P&H8PM7-E;L(/8T.*Q0K%V3@"& M&*G5IXW-.9,JP-N$5X\U;_:E]UT7@\%6TVY;;43+E8W\"N4,^*BUJ1TYS;\X M=80RO6/*)CJP32C2</I M2,+#49)'5B01V6D`UK3F5.K2W>+J;X<3NO)K!A"/PVJ1*!B890_0PZ+[2+G\ M7S[?WMS4HEN5@'M:;7>*LMM'HW9U..H+90:S[-L$X+<-3YZ)?;CC$&1BK M]$*U=*B:YY0=<@_L;Z+WC4Y\G'FDMBTSU]U*DVP.5Q8\+.L`Q,7(]?1ZR#\35]3JC+; MLXB>&4D9?!V+0I^3524MNNS.."*LX9[H;L'HU_J7F+S2\YTIJ]E+0>)=5NZTBE_6W?UBS.*-:TE.XI,/>G.E)\_I@=58'>M7$C9"!(5"]DP M;62ORM827>'O!77LFIV657./D(>D_=(13E?58M#Z"\KB/Q\3 M4UAQZ:/)-832.7+^_P"56/882.MX'(YC6-H4=Z!"NWA:$C([(?T1%D&JF95/ M,WG*PK1"VE/K*L454^%^]6LJDE0"+OA^M,6=ROTO4MJ7.=J!25R)UYTYUL4O M6902!QF2WZ3FD8F8H&>!_PRK``%:)@^ MGRSV94W4_*$-KJ03:K4)6!2F_*/1-O=!QH[*HGI80?[]6)-:VE8`*J4>;C[R M$12*Q[<+8CD@Q9JLA=>;9;F_*BV;[RYOL>:4?"^M,(XZ#%NDM$"%C5MWC!K] M)B*>^U,Y02[EGT0MLNT. M+6E39MY249>$2,4^*IF2($RGMW>)D"?6DIZB7?ZU.%9NMTY+P*J[PH?#13/\L^F)JM$?TZ<_P"_5U[>II&OQ`JA&5:D M87T`-#3FF:K^/.'UP1+TLD;A.TZX!;7"Q$S.>0=M9H5S*XY9S&X2>CR&C93% MS,)(!Q9D//BA%!LHT%U],NIN^U42EQCKG!KRWPM-%X^NFIT:MY,G48(D'!K2 MH!_D/]NHCW0-[UVF*-=>SW82E4J5CC=8?_`[[AO^9"E=O-K$U/?4ON&N\QZ[ M:=,3S&_-X*W]5?&1U1$1!^5T.KO?EW="Q7O.,=!'XW#:>A=9M-^Q051,EQL0 MJBY[S![UE'47531E+:P`EB75-1FC:5DS]=6.]EZ:0Q&>I553O9+2U+?],[I7 MF7LN]BUO+?!=BPGO5S>LTBY")514W.E61&)CGDBA98#:762E71JE+,Z)AH:, MF"Q^/"!U"U_$:E:>V`SBLD+."HQWT=Z@2=(^?/GFR.I.F-VWX4RVEYMNT M^YVNP8&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`& M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`I? MU6GTJ!:R>R*IO.IZFKB(T#Y1RK^A.B'7)1$V(M>5HV/5_6-) MUU;JUVQ"MYI,V,1G\OH?9]!85*JU?BH&9922-VBV.C+!D4?>2H''9$]B[Z'! MY*.$'0SY\^>I84XV>)5U/-]L>HNKK3H*!;3.;`[-VTUD%P=24?Y6C^*U^XCU M$1*G=M!D=OY%Q^V$9J_=AAXT38,G3GDI/09^/M8,EX$%BD`WNXJ2?DG/+XS' M*[HLZA=]B0:F^M53\TDMBO>>;\$UE$K(5;5U'I?+X\;B="S)TH5W"USO6NQ2 M)2&V)37#UR,KALDX;0S\IVU;2CP@7U$B]/53%^O6=ISN:0&^0J;M&P^56)3\ M+C5<[.!\550J%P=>&Y>6CY M08VOX0YEM:O%RAV"CJX!ZCX@0A[B8L)?/(^23.N+#"`FY%W7C%.T+C$D;E?D[M@:'%3P[5<8CK*O8I?4\NNJ$3$\\FJP2!\YBKH@X\(5EE21X0 M[3*OG9IDE-88_EE>R$*&:2H/*W"3HS%P(NE<\0]KN&[3@VZ8?(/>3^%6C$HW M4D,@5R1&MNBIWM(II.9#&X6,`4Q4].3O4B.:3"I]9*E.';V]8[N*BLXA8L$[ MC$2D$]6*/8\\'C%@5*E2[2N-V^O1WDL;:_6,ZJZ*5>D"B4-F.C<9&CR)$JK[IL-'NA$IWW M2Q.9_8^=&=E3.WK.C`$C5(.*US8)KH*-PD[^]BK^?IE*$D(0:Y6F,*=0@4(! MMY,P+/MOT8^7&G@`D%206])H&]U`0.F$[S$3Q?K/V/%85H6S&KJZJCLSZ`A] M1U/%.MS:4T"+*TN7OG$?S]B.HA:U^F0@.*RZ[RU4-GK&QIQM9MB1&GV]KB: M_F5JPNL>8H_9$>5CL>JZ*V=9GWNPW<08?M@:X"G8I"P=B1$T=:3F)&@MQ[QR MXSBTWYC9K&0N^.F2,$H=V4G8\<2$=R3+GN]&$FB,./V!(HXWM"1B(+&OW;!? M054L2;2"_9'%@2.$PO?5\=2T"!](J28R+94(4OM*OTGOX,TR6]0W\\DUMS(/ M:#J,1.OAE:VC4U?,HM7CL/=D7L#J^RN?!L/>ECL2)2Y^'D4/I^)RF-/X:>CT MG;2GI-C^N+$10^&@6XL+W3=[0D_.[MTV)3Y*OZ^)=T!_#>SBLFDS"157K7"3RM@Y*#D)+0T"EDU/60GO9"A^_`Q5X$ M),HM&:AC$)?,XX4:C&9G9-[&?N(\FX>CQS1R&\9&PTYZ3Z>/7J>3L+O2TJ6> M]*PJ(P:)A'D#J2W'=461(#,G.,9%:$'Y2D/2Z0Y1M&:\E$$`R$.'!$W'M4V? M-(/,)%%PNU@@VQB)E&*2XM-,Z;Y:37=I=+R,42KQ`=%J@+^0:0A6DO5)D3@B//X-/W\9<#Y@ MN%C@D3OQMLW'/IW,>8[%-4)A8LL@8WPL.$S$=+&P0HF>T><^ MVYUO(ZXMPW#!E?QLS#(";Y:C\_+%9R\"3IV]ZOMEU4L0=5]#48D4'GQT8)IM MR!!8K)0RLH6U/QV/I)%HYML4$BV>?13S8PT6Z>L>8TM'5J-K*/SOHB!1A)`:0TFI.,Q3WV&CPLO!TY\;=$X[^D=2\'&'6&O7%;DK'4B8NOD4) M6I#QT;]F;.4G7;X1%8X9.&%O&@T:W3C1UT:4D-4EFVSS6QJ7(0"XD$Q`RPF` M08(U#^?._#E;%;)IW?94#D]VC`E;!YP!IO>\+`F)*8V.G'2C:`5!*:[`D(]` MA45J%5L_)OF,Q>D@24M*[+-G0O\`0&)422*(O!`NG%\Z8MS/7IZGFF_<5J[L M8%)Q`.N8E&)5=,I#QL&SL9F?M>4PFI;+EE8SH5,(":@C;V,I&"@D.L2.1$J= M7@)O?DFE,Q@%;5W7,#4\$(;P\!;D^9\^M;JFIR>3P57P9=.ON&N%^@)NA$QU+)\U+=SL7"J?M:1VC;D#BJ5 M>PT-7EFS*_X/&2#BR':UL#2//.NK60%)+6_[,1&-@TH)^;N0:S"9/%&,6?0V M0O?U&TX:C@PFFS?$/%K]9^W)%$X^0FVXP]6:BZ"C!G0Y9O540@"J$YGY+8A& M.1)R:@4\.S-*+TW(58D6E1EN%6C8]KH?#AXU^[I4?/\`G[8:@3P:5SQ.-U// MS@UE3Y&;%;,+&DD:J5A)([!H5;][RE&?V<-"'`5<56'HPL2A<,:P.J2@DL?= ML;4?JB=I!(7[9`H%62>30L-+,5`X0G%^%9N=FR8!TSNK"74[&E M&3?^(ODA!AIZVB?+._+C/)@4_D=L4F]B;'RE8U#V,GCCX2XDYZ:RZ0"15P*R MFYH"$B+KV%U;(=X6T+2>K0KF+[7:A4SZ:CIJJ&8-QL]AQ2&D0T]?3:$YS?.T MXO",?4/=73\[%TT`:T]3)^13J2513CR7F+=E4;9/[-FO!XSMPO+%H^&IHTF/ MB;&.IE(SJ-8O%GQ"0D!WZ;[2)9NG"@-*]XR\3_5')J0_Y<3IN)DK'$\:' M^L'`:>OS5',^GB6`C75E^23HZL::-PBM(8BC:,OBMG)A)L;F#,( M6C1(I7D8=I%QSZ3OA$@:*LV"#O>-,B;(C^B.O!`<(49VE6ZQRR-.KN][=KRO M.AB-;PB$BM8ZMU'4%9RTA-G#V=`[=H3EJQ^B%IQ*JW=0!_'T(4LRKDZT`,E9 M`7=$%G-=ERK+]OSYVE%P5*M?AOLW'GY=R5.L>@;LYXIQ""PC>-R&YD./^D+M M+6E9,R&!!@AQSK$JY9G";-0957LG)JD([NE+4X`@!V&/93*K0LR2P&GWA"3!D%)6?A%XAH#;@Q= MM'*^`,P`:KZPE(JZ!C=72224Y#8[831R1(.X@J:)!IWG"4^*E>;L00C\CMLN MZPI:SV,>:-J^C1RGQ]S."LKCQJ[++UX\!G]@O6OQ M>VIVN(A))U+84A$*\B#B2N8`V]L/V8CR#!"*)28HUV@4K*CV@NE7N_*WY],Y MGG;H=!^7.@7=]1"1/9,$'0R=PZ;F(/*H3HE/!9D(2&1^'RO5$S'[*@E>R86_ MVCT\BY/=-J,.QQT+-@C@&6G!)YBMJ,M1\7V;+.X(,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"LELW^-B\_3H]E1]IWC(S]=.YP;`P-I M4R@9I"'9I:(JZR!2UK/KI@]T)O\`]0SV%L=2_P":U_,]>)IHJ>>;BI;RE?K] MD8.L#/'<&`QNA88WHBK6A6939A#*+\*56(?R&1UW9DDCY@U'(*(-/_#3Q";0 M(H417:MW!\00#_DG68*3@R0@2#G-WR[[]?$_EU:W!J"DUN%[9/(R*LB4WJBQ M;3=3&FTU#JJ8CQUO6LUFZI'S8FIH!%^.=X<=)K[:B!WBWH[QDT\V3#ZL7YB_ MF;77T@YTVA4R@D4CM?0JKJRLD?4SV.J1^(12MMYA(O(1)@3*-BV_B,;=I28W M9,61!?DM4')N7E-&K%JX).&N[H+]YO\`/(]1:57$"'I2`)/G;>3B M]1#P@)T&Q%&3MI:7)-*X/1F$[.B_OFNQ9UZX$OF_1WS\1L,6L#D(>,J>OH5-^; MF(:1[_>:,A$6DE8MAAY083(I^%JGC0E[HU*;CS*1;3]=#V2^S0FF1U_-3=:. M?/`O>9Z_R:F+LW@B:R*JP`6P>0I;+8.0:QRD0HN64R>D4/*^"Q^[$#58UH_= M$X^0\"LA6S47$46CG[6T'^HH?I$&WN@?4IRN<^IB*.Z(X9-UB3Z3JV;<\P"+ MV0U@\VM"6)&ZKA)AG(;"':'(V/N\D,*):C;#7W.N6RHN7%%C.IECMG#X3%2%?.Y)O%!*8G]I6$SC8A90 MIM'AJ4A!?MV6(,O1K-,X)^V$$]2;/\\+YOW]RLYCH3D?92[+GLZC"<2F%6U) M&9!*S%@40)>V],J1M-Q/(U"$P@H0UDMAO!-@/8#-0#>K):TCDX9>LMDIA`@+ M`FQ6>"P[)/+V>_M:U\=2TD(JJAWC,-842IVM`KJ45J`C+4NTKN(BCRE9K@1C M<-!7KQB,\<^15B";C!2,5_5*@VC)BU8(-?TK5#3427B79\[F<"TE3$:!(Q>. M5'6`",MFWK)O'0L!B@H$@S].)2;UHB(8B4!Z3;V2((R'U#1OJEZ<12+>Z?KT M]''@DF9,UI7$BEL-=5O%%/S/-OQ[?4#*IQ&*(@@L72C$>2C4<_;W[>CJ84;H"`_M)PQ= MQ3[*)U;>,!?[9=#!KF/?H6Z'V5P/8K#?TRC1OLF!JIFEZ=D0#>*2"IZT.Q90 M)%(TI&C,$BY,`I'((Y?/(.`W#O12X[<)#790FZB@K9MZQCSDB^7$(,U7;C90 M)?)XU:'HY/=&L5=N`#!)_JZ2'#%/TS'1OIII^$0]Z]=U^ZW,J.H+#G.\B: ME6,@W7C`1;^6;;NF;LD_<-E4UGCC=067R_,V]E5E8CD=VP^N8&P;J"' M$?4091"/M4=P+P!'(H[";I(#]--A#J+P^)1MP-VU]9K@(M'`ZJ.PX(,;M1)? M)#$7Y#J6*WX2Z,::FG\\=,C#$2B2_;>XZ,I'V@H>4T%DF,;834HTT&B$14<# M3&7RF/P(,Z)!:]$1000]R7)33M1SD%I%YM5E<3",IR%[+DX[* M81&9`"3EA-X1(DI/H(+#'8_60D"!@L_>FM6_A)V\*$72[E1=ZYW5$E\F46KB MO7/ICUQ`X8X]D+`P*/\`JT7!J^G!DAU'Z'QQCW=CM]S8'-!(O0PS>_GMR>HT M?J]37\9M_$P/X.UI7$I&RP-)H!"9$'GR[%S.A1V*@BXV:.1C0:/&N)8Q(,'# M61KCV`8.R8JF$GBC1H)&MD-DT6+71(),*UI"EF1F'R)G4%7M)!7@/2,P`ZU@ M$40,P:-IHNVRNTM6_B;E;7<)?)DHS5-70 MID+'0VMH#$AX,MJ>"L(S#HZ!9!SFL:6AFID6U%#FB`\MK#W"\4U(M-$7GD:7 M6!>+?:U-VNP3\]?'O&J;%Y%)"=<#%"AJ-.V2*+-R").G M(M=JDFW5:[(Z:Z>!+Y/;.ZPK2T6(X99M>0:Q1H0;LB*;9PNWT?-DTG.J"ZR6JOB:F^NP3&#(-H-"F:XMTSA\6:N0A9O1YPV+62::J,"YE@2(L2I)ILD\(LW[UL\661=+Z;@:TE25,H M2*.R]"HZQ1ED0!LHO$I0E`HJG(HO&AFBR0V.QTWH)\)!`8]-PX39"1KELP:: M+K:(-T]5=_-@E\GTB5,T]`&R;*"516L*9I%B)])I$H+%XVV2.F!GV4N:30#B MV:6A8H&_\)(DM=?'CX9_W!RLJU_JL"7R>3VB:0].L93[3=5>R89&TX:-D?M> M1'TZ/B"09['$HJQ+^B/N#2-IQXB0`I@T'"8S0,_>B]6OC%TNAN$ODRD.J6JJ MZ;B6E?5G7T%:`&QYF":PZ&1R,-PK25/!)&3M1*(0:Q3&MI&0`@WQY!GJBD8> M!1+HAJX7',]T0DD'`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8!5:>\BU-:W0@2^+2A]=V5^V*M0KZ+16?UK&YC^V3",WWF7[V`')%]Q M^T$MOZ@=^0.#MG7GZ9)Y]W]_#HUT%EI0K7DK$2^.,NYGC&4C+R5CHYU84]F$ MNWCL7F@"62"/3?JR].FMX"Y=";C:UQ(A#%"\2T`&E+-JNQ"L.72D%B56I7V(C33MJMN+4J?5;=8NN&I9C><_NH])ZG^6G3 MD-XY^/GJIA9,HD%AQI[#T3)`M#(RPC4H#EF52553<>+QAH7E91FV-AY1!1,_ M$%EC":H)XLAHW2(.PB+LI'A]M@G-2V_RW_!B17QIDGS^LID7M[\1Y]`Z89]! ML=-+:0"V+/X'=]@]*2^=QD="+JK.)M7\\M>W[$(^H6?!+3&QO9Q&BL=$C'0@ MNRD=&JT=XQ:4EQ.$MT>Z`_&M+`%CPZP9OT/Y/%(:1KEZ@/=0:;[:%-JWM!Q9 M3%XFSD]Y2^&P5T5<./6BX6J81`X&'>(MR@*&LDT4QNH:K0ESZIKC^28NCN'= MKZN5G:C>RG4;'%H)7=:V!#W2EK[#C<7K:RY)9`EP$0KR[*LC?IM^M,9(*?[6 M9%;4!(J:18R-!,U(^4&RH1.%_C?NG]C4"7Q[.T]*B)QFVA0R4TLK,"\7BFCR4@&<^#NGXDG'I2 MU]SYU-\>CZOK2@5K2"W@LG+Q.PG-CE0X:I_VD"*F7LK^2*7.6@5JM8UM,&Z)-V<-:6RR: M2LC&V`N4ZNZSR_Y_@Z1VOQM9%E27I<6UO"&QZCNMFT9"W%!5:4,F;-]B3&M@ M=53*.0NV/+K%1B/^3:)"'+'8F4IJ2O8_]X>K,/7#Q%B[;")I1:ZQ>V6\1.>I M#VWQB.DI-)#S2Z]E$VMCR^VZJ3D`>V99M%)E+.M:[["682L$=Z$QX8XL- MN31E4@+[*!JM$<[\J./:#8X=\>K"(1:$1Q"RVCA:&U=\;];?=$J\19*D??C^ MZ(D]_NC?Y.LO7W9^W.YDR\><#OU3K]C+)*R!1_-]W>PE(-7O4_[E!"XCXMYB MUBM(-2W0P=::\X0OGZN:M.P>N[*IT"_B-"UU>]:M?9ZTK/HT'8+^0R0-T%+' MWI&'6C"@X$N*$*-XZ1#$96"D(KJN[9;=W.6GNNFZ?G9RANQE#> M3*2D'5PISN@!)B/&:M=0Q.,N-D')R838Z[&EB2A(T,8%SI%Z`;O_`+6N8/+I MK&'8RW/KZMLT6)\0P\>)CC MH^&+1:/06#Q@(V;QI\+/Z'(ZU*,)(<*FU)24'$!1]EY&/`<>:1P4[C#H6>7? MR26)2$>UC`CO?ELW[!!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 C`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`__]D_ ` end